Word,Tag
#2386495-05-Discussion-p01
*,O
*,O
IGNORE,O
LINE,O
*,O
*,O

,O
*,O
*,O
IGNORE,O
LINE,O
*,O
*,O

,O
*,O
*,O
IGNORE,O
LINE,O
*,O
*,O

,O
Discussion,O


,O
The,O
APC,B-gene
mutations,B-mutation
identified,O
in,O
the,O
Swedish,B-ethnicity
patients,B-cohort-patient
are,O
scattered,O
along,O
the,O
APC,B-gene
gene,O
(,O
Figure,O
1,O
),O
.,O
 , 
The,O
most,O
5,O
',O
situated,O
pathogenic,O
germ,O
line,O
APC,B-gene
mutation,O
identified,O
in,O
this,O
study,O
,,O
in,O
codon,O
24,O
of,O
exon,O
1,O
(,B-mutation
c.70C,I-mutation
>,I-mutation
T,I-mutation
),I-mutation
,,O
was,O
detected,O
when,O
analyzing,O
patient,B-cohort-patient
C157,B-cohort-patient
.,I-cohort-patient
 , 
This,O
may,O
be,O
the,O
most,O
5,O
',O
location,O
of,O
any,O
mutation,O
detected,O
in,O
the,O
coding,O
region,O
of,O
APC,B-gene
(,O
Figure,O
1[38,O
],O
),O
.,O
 , 
Codon,O
24,O
is,O
within,O
the,O
oligomerization,O
domain,O
at,O
the,O
N,O
-,O
terminus,O
of,O
APC,B-gene
,,I-gene
encoded,O
by,O
amino,O
acids,O
6–57,O
 , 
[,O
39,O
],O
.,O
 , 
The,O
most,O
3,O
',O
situated,O
mutation,O
identified,O
in,O
the,O
present,O
study,O
(,B-cohort-patient
C159,I-cohort-patient
),I-cohort-patient
is,O
a,O
frameshift,B-mutation
at,I-mutation
codon,I-mutation
1920,I-mutation
.,I-mutation
 , 
The,O
most,O
frequently,O
found,O
mutation,O
was,O
the,O
well,O
-,O
known,O
c.3927_3931del,B-mutation
AAAGA,I-mutation
(,O
amino,O
acid,O
position,O
1309,O
),O
mutation,O
detected,O
in,O
10,B-size
out,I-size
of,I-size
the,I-size
95,I-size
patients,B-cohort-patient
.,I-cohort-patient
 , 
The,O
recurrent,O
mutation,O
c.3183_3187delACAAA,B-mutation
(,O
amino,O
acid,O
1061,O
),O
was,O
found,O
in,O
four,B-size
patients,B-cohort-patient
.,I-cohort-patient
 , 
The,O
frequency,O
of,O
de,B-mutation
novo,I-mutation
mutation,I-mutation
cases,B-cohort-patient
was,O
16,B-size
%,I-size
which,O
is,O
lower,O
than,O
the,O
estimation,O
of,O
20–25,O
%,O
reported,O
by,O
Bisgaard,O
et,O
al,O
 , 
[,O
40,O
],O
.,O
 , 
The,O
most,O
frequent,O
mutation,O
occurring,O
de,O
novo,O
was,O
c.3927_3931del,B-mutation
AAAGA,I-mutation
(,B-size
3,I-size
out,I-size
of,I-size
10,I-size
cases,B-cohort-patient
,,I-cohort-patient
30,B-size
%,I-size
),I-size
compared,O
with,O
mutations,O
at,O
other,O
sites,O
in,O
the,O
gene,O
(,B-size
7,I-size
out,I-size
of,I-size
55,I-size
cases,B-cohort-patient
,,I-cohort-patient
12.7,B-size
%,I-size
),I-size
.,O
 , 


,O
Genotype,O
-,O
phenotype,O


,O
The,O
clinical,O
characterization,O
of,O
the,O
APC,B-gene
-,B-mutation
mutation,I-mutation
positive,O
patients,B-cohort-patient
is,O
summarized,O
in,O
Additional,O
file,O
1,O
and,O
the,O
characterization,O
of,O
APC-,B-gene
and,I-Disorder
MUTYH,B-gene
-,I-gene
mutation,I-mutation
negative,I-Disorder
patients,B-cohort-patient
are,O
presented,O
in,O
Table,O
1,O
.,O
 , 
Probands,B-cohort-patient
with,O
mutations,B-mutation
between,I-mutation
codon,I-mutation
1250,I-mutation
and,I-mutation
1468,I-mutation
in,O
the,O
APC,B-gene
gene,O
,,O
which,O
predict,O
a,O
severe,B-Concepts_Ideas
course,I-Concepts_Ideas
of,O
the,O
colorectal,B-body-part
polyposis,B-disease
[,O
41,O
],O
were,O
significantly,O
younger,B-age
at,I-age
diagnosis,I-age
compared,O
with,O
those,O
with,O
mutations,O
outside,O
this,O
region,O
and,O
seem,O
to,O
have,O
more,O
colorectal,B-body-part
polyps,B-disease
.,I-disease
 , 
Despite,O
a,O
lower,O
fraction,O
of,O
patients,B-cohort-patient
with,O
dense,B-Disorder
polyposis,B-disease
among,O
those,O
with,O
mutations,B-mutation
outside,I-mutation
codon,I-mutation
1250–1464,I-mutation
,,I-mutation
CRC,B-disease
at,O
diagnosis,O
occurred,O
often,O
.,O
 , 
High,B-age
age,I-age
at,O
diagnosis,O
can,O
probably,O
explain,O
the,O
relatively,O
high,O
risk,O
of,O
having,O
CRC,B-disease
at,O
diagnosis,O
in,O
this,O
subgroup,O
of,O
probands,B-cohort-patient
.,I-cohort-patient
 , 
Early,O
detection,O
because,O
of,O
short,O
patients,B-cohort-patient
and,O
delay,O
by,O
doctors,O
may,O
explain,O
the,O
relatively,O
low,O
fraction,O
of,O
patients,B-cohort-patient
having,O
CRC,B-disease
at,O
diagnosis,O
among,O
those,O
where,O
the,O
site,O
of,O
the,O
mutation,O
and,O
clinical,O
features,O
indicate,O
a,O
more,O
severe,O
phenotype,O
.,O
 , 
Overall,O
,,O
the,O
risk,O
for,O
a,O
proband,B-cohort-patient
of,O
having,O
a,O
CRC,B-disease
at,O
diagnosis,O
was,O
lower,O
than,O
previously,O
reported,O
by,O
Björk,O
et,O
al,O
 , 
[,O
33,O
],O
where,O
67,B-size
%,I-size
of,O
the,O
probands,B-cohort-patient
diagnosed,O
between,O
1912,O
and,O
1996,O
had,O
CRC,B-disease
at,O
diagnosis,O
.,O
 , 
In,O
this,O
previous,O
study,O
a,O
continued,O
decrease,O
in,O
CRC,B-disease
morbidity,B-Concepts_Ideas
among,O
probands,B-cohort-patient
was,O
seen,O
over,O
time,O
being,O
48,B-size
%,I-size
in,O
the,O
last,O
period,O
studied,O
(,O
1977–1996,O
),O
.,O
 , 
In,O
this,O
current,O
study,O
84,B-size
%,I-size
(,B-size
27,I-size
out,I-size
of,I-size
32,I-size
),I-size
of,O
the,O
probands,B-cohort-patient
were,O
diagnosed,O
with,O
FAP,B-disease
during,O
that,O
period,O
or,O
later,O
(,O
after,O
1976,O
),O
.,O
 , 
Nine,B-size
of,I-size
the,I-size
27,I-size
(,B-size
33,I-size
%,I-size
),I-size
probands,B-cohort-patient
had,O
CRC,B-disease
at,O
diagnosis,O
,,O
which,O
indicates,O
a,O
continued,O
decrease,O
in,O
CRC,B-disease
at,O
diagnosis,O
over,O
time,O
.,O
 , 
This,O
is,O
in,O
agreement,O
with,O
our,O
other,O
findings,O
.,O
 , 
Except,O
for,O
more,O
rapid,O
detection,O
of,O
symptomatic,O
patients,B-cohort-patient
with,O
classical,B-Concepts_Ideas
FAP,B-disease
in,O
recent,O
years,O
,,O
a,O
shift,O
over,O
time,O
of,O
probands,B-cohort-patient
being,O
diagnosed,O
with,O
FAP,B-disease
towards,O
a,O
less,B-Concepts_Ideas
-,I-Concepts_Ideas
severe,I-Concepts_Ideas
phenotype,O
,,O
might,O
explain,O
the,O
decrease,O
in,O
CRC,B-disease
morbidity,B-Concepts_Ideas
.,I-Concepts_Ideas
 , 


,O
 , 
#1360090-03-Results-p02
*,O
*,O
IGNORE,O
LINE,O
*,O
*,O

,O
*,O
*,O
IGNORE,O
LINE,O
*,O
*,O

,O
*,O
*,O
IGNORE,O
LINE,O
*,O
*,O

,O
Clinicopathological,O
and,O
molecular,O
features,O
of,O
BRAF,B-gene
mutant,B-mutation
colorectal,B-disease
cancers,I-disease
stratified,O
according,O
to,O
microsatellite,O
instability,O
status,O
.,O
 , 


,O
aTumor,O
-,O
infiltrating,O
lymphocytes,O


,O
Clinicopathological,O
and,O
molecular,O
features,O
of,O
BRAF,B-gene
mutant,B-mutation
colorectal,B-disease
cancers,I-disease
stratified,O
according,O
to,O
methylator,O
phenotype,O
status,O
.,O
 , 


,O
 , 
#1601966-04-Discussion-p02
*,O
*,O
IGNORE,O
LINE,O
*,O
*,O

,O
*,O
*,O
IGNORE,O
LINE,O
*,O
*,O

,O
*,O
*,O
IGNORE,O
LINE,O
*,O
*,O

,O
For,O
a,O
more,O
detailed,O
survey,O
of,O
congruence,O
between,O
gene,O
expression,O
and,O
chromosomal,O
aberrations,O
in,O
CRC,B-disease
,,I-disease
we,O
compared,O
our,O
results,O
to,O
six,O
previous,O
studies,O
reporting,O
chromosomal,O
gains,O
or,O
losses,O
in,O
distinct,O
chromosomal,O
regions,O
[,O
18,19,21,O
-,O
25,O
],O
(,O
see,O
Tables,O
3,O
,,O
4,O
),O
.,O
 , 
We,O
considered,O
only,O
those,O
chromosomal,O
regions,O
that,O
were,O
reported,O
by,O
different,O
researchers,O
or,O
were,O
found,O
to,O
be,O
aberrant,O
in,O
>,O
20,O
%,O
of,O
tumor,B-disease
samples,B-cohort-patient
.,I-cohort-patient
 , 
In,O
summary,O
,,O
we,O
found,O
that,O
the,O
majority,O
of,O
deletion,O
regions,O
show,O
a,O
reduction,O
in,O
expression,O
.,O
 , 
This,O
suggests,O
that,O
regional,O
transcriptional,O
silencing,O
in,O
CRC,B-disease
is,O
mainly,O
achieved,O
by,O
loss,O
of,O
genomic,O
DNA,O
.,O
 , 
In,O
contrast,O
,,O
amplified,O
regions,O
rather,O
show,O
heterogeneous,O
expression,O
changes,O
.,O
 , 
We,O
found,O
regions,O
of,O
expression,O
gain,O
in,O
the,O
most,O
frequently,O
reported,O
regions,O
of,O
chromosome,O
gain,O
on,O
7,O
,,O
8q,O
,,O
13,O
,,O
20q,O
.,O
 , 
These,O
regions,O
are,O
in,O
support,O
for,O
a,O
positive,O
correlation,O
of,O
DNA,O
copy,O
number,O
and,O
transcript,O
abundance,O
,,O
although,O
a,O
direct,O
causal,O
relationship,O
is,O
not,O
shown,O
in,O
this,O
study,O
.,O
 , 


,O
Expression,O
in,O
Islands,O
frequently,O
amplified,O
in,O
CRC,B-disease
.,I-disease
 , 


,O
Literature,O
survey,O
of,O
chromosomal,O
regions,O
with,O
evidence,O
for,O
amplifications,O
in,O
colorectal,B-disease
cancers,B-disease
.,I-disease
 , 
We,O
checked,O
all,O
regions,O
of,O
frequent,O
chromosomal,O
amplifications,O
for,O
congruence,O
with,O
expression,O
patterns,O
.,O
 , 
Congruence,O
between,O
literature,O
CGH,O
data,O
and,O
our,O
expression,O
data,O
was,O
declared,O
on,O
the,O
presumption,O
that,O
allelic,O
gain,O
causes,O
mRNA,O
up,O
-,O
regulation,O
.,O
 , 


,O
However,O
,,O
there,O
are,O
also,O
many,O
regions,O
of,O
frequent,O
deletions,O
that,O
did,O
not,O
show,O
alterations,O
in,O
expression,O
or,O
that,O
were,O
even,O
down,O
-,O
regulated,O
(,O
7q11.2,O
-,O
7q12,O
,,O
9q34,O
,,O
12p13.1,O
-,O
13.2,O
,,O
15q22,O
-,O
15q23,O
,,O
16p12,O
-,O
16p11,O
,,O
22q11,O
;,O
compare,O
Tables,O
3,O
and,O
4,O
),O
.,O
 , 
One,O
possible,O
explanation,O
is,O
that,O
these,O
down,O
-,O
regulated,O
regions,O
are,O
not,O
amplified,O
in,O
our,O
tumor,B-disease
samples,O
.,O
 , 
An,O
alternative,O
explanation,O
is,O
that,O
the,O
influence,O
of,O
chromosomal,O
amplification,O
on,O
transcription,O
levels,O
can,O
be,O
either,O
positive,O
or,O
negative,O
.,O
 , 
It,O
is,O
possible,O
that,O
amplification,O
of,O
a,O
particular,O
genomic,O
region,O
disrupts,O
transcription,O
of,O
amplified,O
genes,O
by,O
a,O
yet,O
unknown,O
mechanism,O
,,O
e.g.,O
by,O
induction,O
of,O
chromatin,O
-,O
based,O
silencing,O
,,O
or,O
by,O
separation,O
of,O
essential,O
enhancer,O
regions,O
from,O
transcription,O
starts,O
.,O
 , 


,O
Platzer,O
et,O
al,O
.,O
found,O
amplifications,O
in,O
7p,O
,,O
8q,O
,,O
13q,O
,,O
20q,O
in,O
26%–43,O
%,O
of,O
their,O
CRC,B-disease
patients,B-cohort-patient
and,O
revealed,O
by,O
microarray,O
-,O
based,O
expression,O
analysis,O
that,O
only,O
81,B-size
of,I-size
2146,I-size
genes,B-cohort-patient
in,O
amplified,O
regions,O
show,O
over,B-Physiology
-,I-Physiology
expression,I-Physiology
(,B-size
3.8,I-size
%,I-size
),I-size
whereas,O
164,B-size
of,I-size
2146,I-size
genes,B-cohort-patient
show,O
under,B-Physiology
-,I-Physiology
expression,I-Physiology
(,B-size
7.7,I-size
%,I-size
),I-size
.,O
 , 
Using,O
a,O
different,O
approach,O
(,O
microdissection,O
,,O
oligo,O
arrays,O
,,O
analysis,O
aimed,O
at,O
the,O
identification,O
of,O
single,O
chromosomal,O
expression,O
domains,O
and,O
not,O
at,O
the,O
location,O
of,O
all,O
differentially,O
expressed,O
genes,O
in,O
chromosomes,O
),O
we,O
found,O
several,O
smaller,O
up,O
-,O
regulated,O
regions,O
and,O
no,O
regions,O
of,O
down,O
-,O
regulation,O
in,O
the,O
same,O
chromosomal,O
regions,O
.,O
 , 
Therefore,O
,,O
our,O
data,O
partly,O
contradicts,O
the,O
findings,O
of,O
Platzer,O
et,O
al,O
.,O
which,O
state,O
that,O
in,O
these,O
frequently,O
amplified,O
regions,O
gene,O
expression,O
is,O
rather,O
down,O
-,O
regulated,O
.,O
 , 
However,O
,,O
other,O
misregulated,O
expression,O
domains,O
(,O
see,O
above,O
),O
of,O
our,O
study,O
confirmed,O
the,O
general,O
notion,O
by,O
Platzer,O
et,O
al,O
.,O
 , 
that,O
frequently,O
amplified,O
regions,O
in,O
CRC,B-disease
can,O
also,O
exhibit,O
down,O
-,O
regulation,O
of,O
transcript,O
levels,O
.,O
 , 


,O
 , 
#1266026-06-Conclusion-p01
*,O
*,O
IGNORE,O
LINE,O
*,O
*,O

,O
*,O
*,O
IGNORE,O
LINE,O
*,O
*,O

,O
*,O
*,O
IGNORE,O
LINE,O
*,O
*,O

,O
Conclusion,O


,O
The,O
biology,O
of,O
cancer,B-disease
must,O
underlie,O
the,O
epidemiology,O
of,O
cancer,B-disease
.,I-disease
 , 
Here,O
we,O
illustrate,O
that,O
multistage,O
models,O
provide,O
conceptually,O
plausible,O
solutions,O
even,O
when,O
colorectal,B-disease
cancers,I-disease
are,O
divided,O
into,O
biologically,O
relevant,O
and,O
quite,O
different,O
subtypes,O
.,O
 , 
Ages,O
at,O
cancer,B-disease
are,O
consistent,O
with,O
five,O
or,O
six,O
somatic,B-mutation
oncogenic,I-mutation
mutations,I-mutation
for,O
hereditary,B-Concepts_Ideas
(,B-disease
HNPCC,I-disease
),I-disease
MSI+,B-Disorder
cancers,B-disease
and,O
seven,B-size
or,I-size
eight,I-size
mutations,B-mutation
for,O
its,O
sporadic,B-Concepts_Ideas
counterpart,O
.,O
 , 
The,O
apparent,O
requirement,O
for,O
more,O
than,O
one,B-size
additional,O
somatic,B-mutation
mutation,I-mutation
in,O
sporadic,B-Concepts_Ideas
MSI+,B-Disorder
cancers,B-disease
may,O
reflect,O
that,O
MMR,O
inactivation,O
is,O
commonly,O
epigenetic,O
,,O
which,O
may,O
involve,O
multiple,O
steps,O
.,O
 , 
Ages,O
at,O
MSI-,B-Disorder
cancers,B-disease
were,O
consistent,O
with,O
six,B-size
or,I-size
seven,I-size
oncogenic,B-mutation
mutations,I-mutation
,,I-mutation
with,O
similar,O
estimates,O
for,O
all,O
clinical,O
stages,O
,,O
suggesting,O
that,O
mutations,B-mutation
acquired,O
very,O
early,O
in,O
life,O
dictate,O
the,O
cancer,B-disease
phenotype,O
at,O
the,O
time,O
of,O
transformation,O
.,O
 , 
Better,O
integration,O
of,O
cancer,B-disease
epidemiology,O
with,O
its,O
biology,O
remains,O
a,O
further,O
challenge,O
.,O
 , 


,O
 , 
#1557864-02-Background-p02
*,O
*,O
IGNORE,O
LINE,O
*,O
*,O

,O
*,O
*,O
IGNORE,O
LINE,O
*,O
*,O

,O
*,O
*,O
IGNORE,O
LINE,O
*,O
*,O

,O
Interestingly,O
,,O
a,O
number,O
of,O
in,O
vitro,O
studies,O
have,O
suggested,O
a,O
relationship,O
between,O
MMR,B-gene
deficiency,O
and,O
platinum,O
-,O
drug,O
resistance,O
.,O
 , 
Several,O
resistant,O
sublines,O
of,O
ovarian,B-body-part
and,O
melanoma,B-disease
cell,B-cohort-patient
lines,I-cohort-patient
generated,O
by,O
cisplatin,O
selection,O
,,O
appeared,O
to,O
be,O
MMR,B-Physiology
deficient,I-Physiology
[,O
11,O
-,O
15,O
],O
.,O
 , 
In,O
addition,O
,,O
a,O
colon,B-body-part
(,B-cohort-patient
HCT116,I-cohort-patient
),I-cohort-patient
and,O
an,O
endometrioid,B-body-part
cell,B-cohort-patient
line,I-cohort-patient
(,B-cohort-patient
HEC59,I-cohort-patient
),I-cohort-patient
,,O
deficient,B-Disorder
for,I-Disorder
MLH1,I-Disorder
and,I-Disorder
MSH2,I-Disorder
respectively,O
,,O
were,O
2.1,O
and,O
1.8,O
fold,O
resistant,O
to,O
cisplatin,O
compared,O
to,O
cell,O
lines,O
complemented,O
with,O
chromosome,O
3,O
,,O
containing,O
MLH1,B-gene
,,I-gene
or,O
chromosome,O
2,O
,,O
containing,O
MSH2,B-gene
 , 
[,O
15,O
-,O
17,O
],O
.,O
 , 
These,O
in,O
vitro,O
studies,O
suggest,O
that,O
inactivation,O
of,O
proteins,O
involved,O
in,O
the,O
initiation,O
of,O
MMR,B-gene
might,O
cause,O
cisplatin,O
resistance,O
.,O
 , 
It,O
is,O
thought,O
that,O
the,O
DNA,O
damage,O
caused,O
by,O
platin,O
-,O
drugs,O
is,O
recognized,O
by,O
MMR,O
.,O
 , 
The,O
cell,O
will,O
then,O
undergo,O
several,O
unsuccessful,O
repair,O
cycles,O
,,O
finally,O
resulting,O
in,O
the,O
induction,O
of,O
apoptosis,O
.,O
 , 
When,O
MMR,O
is,O
inactive,O
the,O
DNA,O
damage,O
caused,O
by,O
platin,O
-,O
drugs,O
will,O
not,O
be,O
picked,O
up,O
and,O
will,O
therefore,O
not,O
result,O
in,O
apoptosis,O
rendering,O
the,O
cells,O
resistant,O
to,O
platin,O
-,O
drugs,O
.,O
 , 


,O
Several,O
studies,O
have,O
determined,O
the,O
frequency,O
of,O
MMR,B-gene
inactivation,O
in,O
ovarian,B-body-part
cancer,I-disease
using,O
MSI,O
as,O
a,O
marker,O
[,O
18,O
-,O
37,O
],O
.,O
 , 
However,O
,,O
there,O
was,O
a,O
wide,O
range,O
observed,O
(,O
0%–39,O
%,O
),O
and,O
so,O
far,O
only,O
a,O
few,O
studies,O
have,O
linked,O
MMR,B-gene
inactivation,O
to,O
platinum,O
-,O
based,O
chemotherapy,O
resistance,O
.,O
 , 
Thus,O
,,O
there,O
is,O
still,O
no,O
general,O
agreement,O
about,O
the,O
frequency,O
of,O
MMR,B-gene
inactivation,O
and,O
its,O
possible,O
involvement,O
in,O
the,O
platinum,O
-,O
based,O
chemotherapy,O
resistance,O
seen,O
in,O
ovarian,B-body-part
cancer,I-disease
patients,B-cohort-patient
.,I-cohort-patient
 , 


,O
The,O
aim,O
of,O
this,O
study,O
is,O
to,O
determine,O
the,O
frequency,O
of,O
mismatch,B-Physiology
repair,I-Physiology
(,B-gene
MMR,I-gene
),I-gene
inactivation,I-Physiology
in,O
ovarian,B-body-part
cancer,I-disease
and,O
whether,O
it,O
is,O
associated,O
with,O
platinum,O
-,O
based,O
chemotherapy,O
resistance,O
.,O
 , 
To,O
this,O
purpose,O
we,O
analyzed,O
seventy,B-size
-,I-size
five,I-size
ovarian,B-body-part
carcinomas,B-cohort-patient
and,O
eight,B-size
ovarian,B-body-part
cancer,I-disease
cell,B-cohort-patient
lines,I-cohort-patient
.,I-cohort-patient
 , 
In,O
the,O
discussion,O
,,O
the,O
results,O
were,O
compared,O
to,O
that,O
of,O
twenty,O
similar,O
studies,O
in,O
the,O
literature,O
including,O
in,O
total,O
1315,B-size
ovarian,B-body-part
cancer,I-disease
patients,B-cohort-patient
.,I-cohort-patient
 , 


,O
 , 
#1601966-04-Discussion-p01
*,O
*,O
IGNORE,O
LINE,O
*,O
*,O

,O
*,O
*,O
IGNORE,O
LINE,O
*,O
*,O

,O
*,O
*,O
IGNORE,O
LINE,O
*,O
*,O

,O
Discussion,O


,O
Global,O
analysis,O
of,O
chromosomal,O
regions,O
with,O
expression,O
gain,O
or,O
loss,O


,O
We,O
found,O
that,O
25,O
%,O
of,O
the,O
genes,O
lie,O
in,O
regions,O
that,O
are,O
affected,O
by,O
expression,O
imbalance,O
in,O
colon,B-body-part
cancer,B-disease
.,I-disease
 , 
This,O
does,O
not,O
mean,O
that,O
25,O
%,O
of,O
the,O
genes,O
are,O
misregulated,O
as,O
many,O
genes,O
that,O
fall,O
into,O
these,O
regions,O
are,O
not,O
expressed,O
at,O
all,O
in,O
tumors,B-disease
and,O
in,O
normal,B-disease
epithelium,O
of,O
the,O
colon,B-body-part
.,I-body-part
 , 
Additionally,O
,,O
we,O
note,O
that,O
these,O
numbers,O
are,O
probably,O
an,O
upper,O
limit,O
because,O
the,O
sliding,O
window,O
approach,O
probably,O
included,O
several,O
genes,O
in,O
close,O
proximity,O
to,O
the,O
boundaries,O
of,O
misexpressed,O
regions,O
.,O
 , 
Nevertheless,O
,,O
the,O
number,O
of,O
regions,O
of,O
imbalanced,O
expression,O
is,O
remarkable,O
and,O
suggest,O
that,O
there,O
is,O
extensive,O
regulation,O
in,O
CRC,B-disease
at,O
the,O
genomic,O
level,O
.,O
 , 
Recently,O
,,O
Nakao,O
et,O
al,O
.,O
estimated,O
from,O
genome,O
-,O
wide,O
array,O
CGH,O
data,O
that,O
~17,O
%,O
of,O
the,O
human,O
genome,O
is,O
affected,O
by,O
DNA,O
copy,O
number,O
changes,O
in,O
CRC,B-disease
[,O
23,O
],O
.,O
 , 
Prior,O
to,O
a,O
more,O
detailed,O
analysis,O
of,O
individual,B-cohort-patient
regions,O
in,O
this,O
study,O
,,O
this,O
suggested,O
that,O
not,O
all,O
regional,O
expression,O
changes,O
in,O
CRC,B-disease
will,O
be,O
explainable,O
by,O
DNA,O
copy,O
number,O
aberrations,O
.,O
 , 


,O
There,O
are,O
only,O
slightly,O
more,O
genes,O
with,O
expression,O
loss,O
than,O
regions,O
with,O
expression,O
gain,O
.,O
 , 
One,O
can,O
argue,O
that,O
a,O
tumor,O
ought,O
to,O
show,O
a,O
higher,O
frequency,O
of,O
expression,O
loss,O
than,O
expression,O
gain,O
.,O
 , 
Reasons,O
are,O
that,O
there,O
should,O
be,O
a,O
tendency,O
to,O
lose,O
tumor,O
suppressor,O
genes,O
selectively,O
and,O
to,O
lose,O
non,O
-,O
essential,O
genes,O
(,O
genomic,O
ballast,O
),O
as,O
a,O
side,O
effect,O
.,O
 , 
If,O
transcription,O
would,O
be,O
a,O
process,O
that,O
is,O
predominantly,O
driven,O
by,O
positive,O
regulation,O
of,O
transcriptional,O
activators,O
,,O
one,O
would,O
assume,O
that,O
any,O
partial,O
genome,O
loss,O
results,O
in,O
a,O
slow,O
down,O
of,O
transcription,O
.,O
 , 
In,O
the,O
light,O
of,O
these,O
considerations,O
,,O
an,O
equally,O
high,O
number,O
of,O
regions,O
with,O
expression,O
gain,O
can,O
be,O
interpreted,O
in,O
two,O
ways,O
.,O
 , 
Either,O
positive,O
selection,O
drives,O
expression,O
gain,O
of,O
some,O
regions,O
in,O
cancer,O
cells,O
,,O
or,O
a,O
default,O
phenotype,O
of,O
transcription,O
suppression,O
dominates,O
in,O
normal,O
cells,O
which,O
is,O
relaxed,O
during,O
tumor,O
cell,O
development,O
.,O
 , 


,O
Gene,O
expression,O
in,O
chromosomal,O
regions,O
with,O
frequent,O
DNA,O
copy,O
number,O
changes,O
in,O
CRC,B-disease


,I-disease
Most,O
studies,O
reported,O
frequent,O
gains,O
of,O
chromosome,O
7,O
,,O
8q,O
,,O
13q,O
,,O
20q,O
and,O
losses,O
of,O
4,O
and,O
18q,O
in,O
CRC,B-disease
[,O
18,19,21,O
-,O
25,O
],O
.,O
 , 
These,O
broadly,O
-,O
defined,O
alterations,O
are,O
in,O
perfect,O
agreement,O
with,O
chromosome,O
-,O
specific,O
trends,O
in,O
our,O
expression,O
data,O
,,O
especially,O
the,O
exclusive,O
presence,O
of,O
domains,O
of,O
expression,O
gain,O
on,O
8,O
,,O
13,O
and,O
20,O
and,O
the,O
exclusive,O
presence,O
of,O
domains,O
of,O
expression,O
loss,O
on,O
chromosome,O
4,O
and,O
18,O
(,O
see,O
Table,O
2,O
and,O
Figures,O
21,O
,,O
22,O
,,O
23,O
,,O
24,O
,,O
25,O
,,O
26,O
),O
.,O
 , 
There,O
is,O
a,O
single,O
discrepancy,O
for,O
chromosome,O
7,O
:,O
region,O
7q11,O
-,O
7q12,O
has,O
been,O
reported,O
as,O
amplified,O
in,O
CRC,B-disease
,,I-disease
but,O
its,O
expression,O
is,O
significantly,O
down,O
-,O
regulated,O
in,O
our,O
tumor,O
samples,O
.,O
 , 


,O
 , 
#1601966-03-Results-p07
*,O
*,O
IGNORE,O
LINE,O
*,O
*,O

,O
*,O
*,O
IGNORE,O
LINE,O
*,O
*,O

,O
*,O
*,O
IGNORE,O
LINE,O
*,O
*,O

,O
Up,O
-,O
regulation,O
of,O
mRNA,O
levels,O
in,O
human,O
chromosomal,O
region,O
17q21.33,O
-,O
23.2,O
(,B-cohort-patient
patient,I-cohort-patient
counts,O
with,O
coordinate,O
up,O
-,O
regulation,O
),O
.,O
 , 
Grayscale,O
cross,O
-,O
comparison,O
plots,O
of,O
up,O
-,O
regulation,O
patterns,O
across,O
patients,B-cohort-patient
(,O
analogous,O
to,O
Figures,O
7,O
,,O
10,O
,,O
13,O
),O
.,O
 , 
View,O
this,O
plot,O
in,O
conjunction,O
with,O
Figures,O
18,O
and,O
20,O
.,O
 , 
Note,O
,,O
that,O
many,O
more,O
patients,B-cohort-patient
show,O
up,O
-,O
regulation,O
as,O
indicated,O
by,O
dark,O
spots,O
in,O
this,O
plot,O
than,O
down,O
-,O
regulation,O
as,O
indicated,O
by,O
dark,O
spots,O
in,O
Figure,O
20,O
.,O
 , 
This,O
region,O
has,O
been,O
reported,O
in,O
other,O
studies,O
to,O
be,O
frequently,O
amplified,O
in,O
colon,B-body-part
cancer,B-disease
(,O
see,O
Table,O
3,O
),O
.,O
 , 


,O
Up,O
-,O
regulation,O
of,O
mRNA,O
levels,O
in,O
human,O
chromosomal,O
region,O
17q21.33,O
-,O
23.2,O
(,B-cohort-patient
patient,I-cohort-patient
counts,O
with,O
coordinate,O
down,O
-,O
regulation,O
),O
.,O
 , 
Grayscale,O
cross,O
-,O
comparison,O
plots,O
of,O
down,O
-,O
regulation,O
patterns,O
across,O
patients,B-cohort-patient
(,O
analogous,O
to,O
Figures,O
8,O
,,O
11,O
,,O
14,O
),O
.,O
 , 
View,O
this,O
plot,O
in,O
conjunction,O
with,O
Figures,O
18,O
and,O
19,O
.,O
 , 


,B-cohort-patient
Individual,I-cohort-patient
chromosomal,O
islands,O
with,O
loss,O
of,O
expression,O


,O
1p36.13,O
-,O
1p36.11,O


,O
The,O
most,O
strongly,O
down,O
-,O
regulated,O
region,O
in,O
our,O
study,O
is,O
1p36.13,O
-,O
1p36.11,O
(,O
see,O
Figures,O
9,O
,,O
10,O
,,O
11,O
),O
.,O
 , 
A,O
larger,O
chromosome,O
region,O
comprising,O
this,O
fragment,O
has,O
recently,O
been,O
reported,O
to,O
be,O
frequently,O
deleted,O
in,O
CRC,B-disease
(,O
see,O
Tables,O
1,O
and,O
4,O
),O
.,O
 , 
No,O
tumor,O
suppressor,O
gene,O
has,O
been,O
found,O
yet,O
.,O
 , 
Our,O
data,O
suggest,O
multiple,O
genes,O
that,O
could,O
act,O
as,O
class,O
II,O
TSGs,O
.,O
 , 
Several,O
have,O
been,O
associated,O
with,O
proliferative,O
processes,O
or,O
even,O
cancer,O
before,O
.,O
 , 
The,O
PLA2G2A,B-gene
encodes,O
phospholipase,O
A2,O
group,B-cohort-patient
IIA,O
which,O
has,O
been,O
proposed,O
as,O
a,O
TSG,O
and,O
a,O
marker,O
for,O
metastasis,O
and,O
patient,B-cohort-patient
survival,O
in,O
gastric,B-disease
cancer,I-disease
[,O
30,O
],O
.,O
 , 
The,O
E2F2,O
transcription,O
factor,O
is,O
a,O
known,O
regulator,O
of,O
TSGs,O
and,O
interacts,O
specifically,O
with,O
the,O
RB,O
protein,O
.,O
 , 
It,O
plays,O
an,O
important,O
role,O
in,O
the,O
cell,O
cycle,O
.,O
 , 
The,O
CDC42,B-gene
protein,O
is,O
a,O
small,O
Rho,O
-,O
like,O
GTPase,O
.,O
 , 
It,O
acts,O
in,O
intracellular,O
signaling,O
and,O
is,O
involved,O
in,O
various,O
processes,O
like,O
control,O
of,O
morphology,O
,,O
migration,O
,,O
endocytosis,O
,,O
and,O
the,O
cell,O
cycle,O
.,O
 , 
Therefore,O
,,O
PLAG2A,B-gene
,,I-gene
E2F2,B-gene
and,O
CDC42,B-gene
are,O
the,O
primary,O
candidate,O
tumor,B-disease
suppressors,O
in,O
this,O
region,O
.,O
 , 


,O
Expression,O
in,O
Islands,O
frequently,O
deleted,O
in,O
CRC,B-disease
.,I-disease
 , 


,O
Literature,O
survey,O
of,O
chromosomal,O
regions,O
with,O
evidence,O
for,O
deletions,O
in,O
colorectal,B-disease
cancers,B-disease
.,I-disease
 , 
We,O
checked,O
all,O
regions,O
of,O
frequent,O
chromosomal,O
deletions,O
for,O
congruence,O
with,O
expression,O
patterns,O
.,O
 , 
Congruence,O
between,O
literature,O
CGH,O
data,O
and,O
our,O
expression,O
data,O
was,O
declared,O
on,O
the,O
presumption,O
that,O
allelic,O
loss,O
causes,O
mRNA,O
down,O
-,O
regulation,O
.,O
 , 


,O
Down,O
-,O
regulation,O
of,O
mRNA,O
expression,O
in,O
human,O
chromosomal,O
region,O
1p36.13,O
-,O
1p36.11,O
(,O
T,O
/,O
N,O
relative,O
expression,O
heat,O
map,O
),O
.,O
 , 
Heat,O
map,O
of,O
fold,O
change,O
of,O
tumor,B-disease
-,I-disease
versus,O
-,O
normal,O
expression,O
.,O
 , 
Genes,O
are,O
given,O
in,O
chromosomal,O
order,O
on,O
the,O
horizontal,O
axis,O
.,O
 , 
Patient,B-cohort-patient
codes,O
are,O
given,O
on,O
the,O
vertical,O
axis,O
.,O
 , 
The,O
legend,O
depicts,O
which,O
colors,O
code,O
for,O
which,O
expression,O
changes,O
on,O
a,O
loge,O
scale,O
(,O
green,O
:,O
down,O
in,O
tumor,B-disease
;,I-disease
red,O
:,O
up,O
in,O
tumor,B-disease
),I-disease
.,O
 , 
View,O
in,O
conjunction,O
with,O
Figures,O
10,O
and,O
11,O
.,O
 , 


,O
 , 
#1601966-01-Abstract-p01
*,O
*,O
IGNORE,O
LINE,O
*,O
*,O

,O
*,O
*,O
IGNORE,O
LINE,O
*,O
*,O

,O
*,O
*,O
IGNORE,O
LINE,O
*,O
*,O

,O
A,O
genome,O
-,O
wide,O
map,O
of,O
aberrantly,O
expressed,O
chromosomal,O
islands,O
in,O
colorectal,B-disease
cancer,I-disease


,I-disease
Abstract,O


,O
Background,O


,B-disease
Cancer,I-disease
development,O
is,O
accompanied,O
by,O
genetic,O
phenomena,O
like,O
deletion,B-mutation
and,I-mutation
amplification,I-mutation
of,I-mutation
chromosome,I-mutation
parts,I-mutation
or,O
alterations,O
of,O
chromatin,O
structure,O
.,O
 , 
It,O
is,O
expected,O
that,O
these,O
mechanisms,O
have,O
a,O
strong,O
effect,O
on,O
regional,O
gene,O
expression,O
.,O
 , 


,O
Results,O


,O
We,O
investigated,O
genome,O
-,O
wide,O
gene,O
expression,O
in,O
colorectal,B-body-part
carcinoma,B-disease
(,B-disease
CRC,I-disease
),I-disease
and,O
normal,B-disease
epithelial,B-body-part
tissues,I-body-part
from,O
25,B-size
patients,B-cohort-patient
using,O
oligonucleotide,O
arrays,O
.,O
 , 
This,O
allowed,O
us,O
to,O
identify,O
81,O
distinct,O
chromosomal,O
islands,O
with,O
aberrant,O
gene,O
expression,O
.,O
 , 
Of,O
these,O
,,O
38,O
islands,O
show,O
a,O
gain,O
in,O
expression,O
and,O
43,O
a,O
loss,O
of,O
expression,O
.,O
 , 
In,O
total,O
,,O
7.892,O
genes,O
(,O
25.3,O
%,O
of,O
all,O
human,O
genes,O
),O
are,O
located,O
in,O
aberrantly,O
expressed,O
islands,O
.,O
 , 
Many,O
chromosomal,O
regions,O
that,O
are,O
linked,O
to,O
hereditary,B-Concepts_Ideas
colorectal,B-body-part
cancer,I-disease
show,O
deregulated,B-Physiology
expression,I-Physiology
.,I-Physiology
 , 
Also,O
,,O
many,O
known,O
tumor,B-disease
genes,O
localize,O
to,O
chromosomal,B-Physiology
islands,I-Physiology
of,I-Physiology
misregulated,I-Physiology
expression,I-Physiology
in,O
CRC,B-disease
.,I-disease
 , 


,O
Conclusion,O


,O
An,O
extensive,O
comparison,O
with,O
published,O
CGH,O
data,O
suggests,O
that,O
chromosomal,O
regions,O
known,O
for,O
frequent,O
deletions,O
in,O
colon,B-disease
cancer,B-disease
tend,O
to,O
show,O
reduced,O
expression,O
.,O
 , 
In,O
contrast,O
,,O
regions,O
that,O
are,O
often,O
amplified,O
in,O
colorectal,B-body-part
tumors,B-disease
exhibit,O
heterogeneous,B-Physiology
expression,I-Physiology
patterns,I-Physiology
:,I-Physiology
even,O
show,O
a,O
decrease,O
of,O
mRNA,O
expression,O
.,O
 , 
Because,O
for,O
several,O
islands,O
of,O
deregulated,O
expression,O
chromosomal,O
aberrations,O
have,O
never,O
been,O
observed,O
,,O
we,O
speculate,O
that,O
additional,O
mechanisms,O
(,O
like,O
abnormal,O
states,O
of,O
regional,O
chromatin,O
),O
also,O
have,O
a,O
substantial,O
impact,O
on,O
the,O
formation,O
of,O
co,O
-,O
expression,O
islands,O
in,O
colorectal,B-body-part
carcinoma,B-disease
.,I-disease
 , 


,O
 , 
#1601966-06-Methods-p03
*,O
*,O
IGNORE,O
LINE,O
*,O
*,O

,O
*,O
*,O
IGNORE,O
LINE,O
*,O
*,O

,O
*,O
*,O
IGNORE,O
LINE,O
*,O
*,O

,O
Analysis,O
of,O
expression,O
along,O
chromosomes,O


,O
 , 
In,O
each,O
graph,O
of,O
Figures,O
2,O
,,O
3,O
,,O
4,O
,,O
5,O
,,O
we,O
plotted,O
the,O
numbers,O
of,O
patient,B-cohort-patient
samples,O
with,O
tumor,B-disease
up,O
/,O
down,O
regulation,O
(,O
percentage,O
on,O
informative,O
cases,B-cohort-patient
),I-cohort-patient
for,O
all,O
genes,O
according,O
to,O
their,O
position,O
on,O
the,O
chromosome,O
.,O
 , 
In,O
these,O
plots,O
,,O
the,O
smoothing,O
of,O
the,O
curve,O
is,O
achieved,O
by,O
averaging,O
over,O
50,O
consecutive,O
genes,O
.,O
 , 


,O
Significant,O
deviations,O
from,O
average,O
expression,O
in,O
a,O
particular,O
chromosomal,O
region,O
is,O
not,O
sufficient,O
to,O
infer,O
coordinated,O
deregulation,O
.,O
 , 
This,O
is,O
because,O
it,O
does,O
not,O
allow,O
to,O
infer,O
whether,O
all,O
genes,O
of,O
a,O
region,O
are,O
actually,O
de,O
-,O
regulated,O
in,O
the,O
same,O
subset,O
of,O
patients,B-cohort-patient
.,I-cohort-patient
 , 
They,O
could,O
also,O
be,O
de,O
-,O
regulated,O
in,O
different,O
patients,B-cohort-patient
.,I-cohort-patient
 , 
Consider,O
three,O
genes,O
G1,O
,,O
G2,O
,,O
G3,O
and,O
their,O
expression,O
in,O
patients,B-cohort-patient
A,O
,,O
B,O
,,O
C,O
,,O
D.,O
Each,O
gene,O
is,O
up,O
-,O
regulated,O
in,O
50,B-size
%,I-size
of,O
patients,B-cohort-patient
.,I-cohort-patient
 , 
If,O
the,O
genes,O
are,O
up,O
-,O
regulated,O
in,O
different,O
patients,B-cohort-patient
(,O
G1,O
is,O
up,O
-,O
regulated,O
in,O
A,O
/,O
B,O
,,O
G2,O
is,O
up,O
-,O
regulated,O
in,O
B,O
/,O
C,O
,,O
G3,O
is,O
up,O
-,O
regulated,O
in,O
C,O
/,O
D,O
),O
,,O
then,O
one,O
can,O
not,O
assume,O
that,O
there,O
is,O
a,O
regional,O
up,O
-,O
regulation,O
in,O
all,O
patients,B-cohort-patient
.,I-cohort-patient
 , 
However,O
,,O
if,O
the,O
genes,O
are,O
up,O
-,O
regulated,O
in,O
the,O
same,O
patients,B-cohort-patient
(,O
G1,O
,,O
G2,O
and,O
G3,O
are,O
all,O
up,O
-,O
regulated,O
in,O
A,O
and,O
B,O
),O
,,O
then,O
it,O
is,O
fair,O
to,O
assume,O
that,O
they,O
have,O
undergone,O
coordinated,O
regional,O
up,O
-,O
regulation,O
.,O
 , 
Chance,O
effects,O
more,O
likely,O
create,O
non,O
-,O
coordinated,O
up,O
-,O
regulation,O
.,O
 , 
To,O
capture,O
such,O
a,O
gene,O
-,O
versus,O
-,O
gene,O
correlation,O
structure,O
,,O
we,O
performed,O
the,O
following,O
for,O
a,O
given,O
chromosome,O
region,O
:,O


,O
For,O
each,O
pair,O
of,O
genes,O
of,O
a,O
given,O
chromosome,O
region,O
we,O
count,O
the,O
number,O
of,O
their,O
coordinated,O
(,O
simultaneous,O
),O
up,O
-,O
regulations,O
(,O
based,O
on,O
the,O
above,O
computed,O
fold,O
changes,O
),O
over,O
the,O
set,O
of,O
patients,B-cohort-patient
and,O
the,O
number,O
of,O
coordinated,O
down,O
-,O
regulations,O
,,O
separately,O
.,O
 , 
These,O
values,O
can,O
be,O
represented,O
in,O
gray,O
-,O
scale,O
plots,O
:,O
one,O
gray,O
scale,O
plot,O
for,O
the,O
coordinated,O
up,O
-,O
regulation,O
and,O
a,O
similar,O
one,O
for,O
coordinated,O
down,O
-,O
regulation,O
.,O
 , 
Both,O
,,O
horizontal,O
and,O
vertical,O
axis,O
comprise,O
genes,O
of,O
the,O
chromosome,O
region,O
in,O
the,O
right,O
chromosomal,O
order,O
(,O
see,O
Figures,O
6,O
,,O
7,O
,,O
8,O
,,O
9,O
,,O
10,O
,,O
11,O
,,O
12,O
,,O
13,O
,,O
14,O
,,O
15,O
,,O
16,O
,,O
17,O
,,O
18,O
,,O
19,O
,,O
20,O
,,O
21,O
,,O
22,O
,,O
23,O
,,O
24,O
,,O
25,O
,,O
26,O
,,O
27,O
,,O
28,O
,,O
29,O
,,O
30,O
,,O
31,O
,,O
32,O
),O
.,O
 , 
The,O
darkness,O
of,O
squares,O
represents,O
the,O
number,O
of,O
coordinated,O
up-,O
or,O
down,O
-,O
regulations,O
,,O
respectively,O
.,O
 , 
Coordinately,O
up,O
-,O
regulated,O
regions,O
show,O
up,O
as,O
squares,O
with,O
high,O
",O
correlation,O
",O
measures,O
along,O
the,O
diagonal,O
.,O
 , 
Such,O
resulting,O
cross,O
-,O
comparison,O
matrices,O
can,O
be,O
visualized,O
interactively,O
for,O
any,O
chromosomal,O
region,O
on,O
our,O
supplementary,O
website[41,O
],O
along,O
with,O
heat,O
maps,O
of,O
expression,O
intensities,O
and,O
are,O
used,O
in,O
Figures,O
6,O
,,O
7,O
,,O
8,O
,,O
9,O
,,O
10,O
,,O
11,O
,,O
12,O
,,O
13,O
,,O
14,O
,,O
15,O
,,O
16,O
,,O
17,O
,,O
18,O
,,O
19,O
,,O
20,O
,,O
21,O
,,O
22,O
,,O
23,O
,,O
24,O
,,O
25,O
,,O
26,O
,,O
27,O
,,O
28,O
,,O
29,O
,,O
30,O
,,O
31,O
,,O
32,O
.,O
 , 
Alternatively,O
,,O
we,O
applied,O
",O
correlation,O
",O
measures,O
like,O
Pearson,O
correlation,O
coefficients,O
on,O
fold,O
changes,O
,,O
mutual,O
information,O
,,O
and,O
set,O
-,O
theoretic,O
coefficients,O
like,O
the,O
Dice,O
and,O
Jaccard,O
coefficients,O
on,O
binary,O
patterns,O
of,O
up,O
-,O
regulation,O
and,O
down,O
-,O
regulation,O
(,O
only,O
available,O
on,O
our,O
website,O
[,O
41,O
],O
),O
.,O
 , 


,O
 , 
#1334229-05-Discussion-p03
Of,O
the,O
microsatellite,B-Disorder
instable,I-Disorder
tumours,B-disease
,,I-disease
approximately,O
90,B-size
%,I-size
show,O
absence,B-Physiology
of,I-Physiology
hMLH1,B-gene
expression,I-Physiology
[,O
24,O
],O
.,O
 , 
In,O
most,O
sporadic,B-Concepts_Ideas
colorectal,B-body-part
cancers,I-disease
,,I-disease
the,O
promoter,B-Physiology
region,I-Physiology
of,I-Physiology
hMLH1,B-gene
is,I-Physiology
hypermethylated,I-Physiology
,,I-Physiology
resulting,O
in,O
absence,O
of,O
the,O
protein,O
[,O
53,O
-,O
55,O
],O
.,O
 , 
BAT-26,O
was,O
previously,O
shown,O
to,O
identify,O
microsatellite,O
instability,O
in,O
sporadic,B-Concepts_Ideas
colorectal,B-body-part
cancer,I-disease
[,O
56,O
],O
and,O
results,O
from,O
our,O
study,O
showed,O
a,O
good,O
agreement,O
between,O
unstable,O
BAT-26,O
and,O
absent,B-Physiology
hMLH1,I-Physiology
expression,I-Physiology
.,I-Physiology
 , 


,O
Several,O
studies,O
have,O
shown,O
that,O
microsatellite,O
instability,O
and,O
mutations,B-mutation
in,O
APC,B-gene
and,O
K,B-gene
-,I-gene
ras,I-gene
occur,O
almost,O
mutually,O
exclusively,O
[,O
18,19,21,57,O
],O
,,O
suggesting,O
that,O
these,O
characteristics,O
represent,O
separate,O
pathways,O
.,O
 , 
However,O
,,O
others,O
have,O
observed,O
aberrations,O
in,O
both,O
pathways,O
,,O
but,O
these,O
studies,O
have,O
been,O
performed,O
in,O
relatively,O
small,O
groups,B-cohort-patient
of,O
HNPCC,B-disease
and,O
sporadic,B-Concepts_Ideas
colorectal,B-body-part
cancer,B-disease
patients,B-cohort-patient
[,O
14,20,58,O
],O
and,O
this,O
may,O
have,O
given,O
rise,O
to,O
a,O
relative,O
overrepresentation,O
of,O
mutation,O
detection,O
in,O
both,O
pathways,O
.,O
 , 
Although,O
in,O
our,O
study,O
the,O
simultaneous,O
occurrence,O
of,O
hMLH1,B-Physiology
deficiency,I-Physiology
as,O
well,O
as,O
an,O
APC,B-gene
or,O
K,B-gene
-,I-gene
ras,I-gene
mutation,B-mutation
was,O
observed,O
in,O
a,O
small,B-size
number,I-size
of,O
tumours,B-disease
,,I-disease
the,O
mutually,O
exclusive,O
occurrence,O
of,O
hMLH1,B-gene
deficiency,I-Physiology
and,O
mutations,B-mutation
in,O
APC,B-gene
and/or,O
K,B-gene
-,I-gene
ras,I-gene
seemed,O
to,O
predominate,O
.,O
 , 


,O
Moreover,O
,,O
after,O
exclusion,O
of,O
tumours,B-disease
displaying,O
this,O
overlap,O
,,O
a,O
striking,O
difference,O
between,O
occurrences,O
of,O
APC,B-gene
and/or,O
K,B-gene
-,I-gene
ras,I-gene
mutations,B-mutation
versus,O
absence,B-Physiology
of,I-Physiology
hMLH1,I-Physiology
expression,I-Physiology
was,O
observed,O
.,O
 , 
The,O
differences,O
were,O
most,O
pronounced,O
with,O
regard,O
to,O
tumour,B-disease
sub,O
-,O
localisation,O
and,O
differentiation,O
.,O
 , 
hMLH1,B-Disorder
deficient,I-Disorder
tumours,B-disease
occur,O
almost,O
exclusively,O
in,O
the,O
proximal,B-body-part
colon,I-body-part
and,O
are,O
relatively,O
more,O
frequently,O
poorly,O
differentiated,O
,,O
which,O
is,O
in,O
accordance,O
with,O
reports,O
from,O
other,O
studies,O
[,O
22,O
-,O
25,O
],O
.,O
 , 


,O
 , 
#2386495-03-Methods-p03
*,O
*,O
IGNORE,O
LINE,O
*,O
*,O

,O
*,O
*,O
IGNORE,O
LINE,O
*,O
*,O

,O
*,O
*,O
IGNORE,O
LINE,O
*,O
*,O

,O
Statistics,O


,O
Student,O
's,O
t,O
-,O
test,O
was,O
used,O
to,O
analyze,O
continuous,O
data,O
,,O
and,O
Fisher,O
's,O
exact,O
test,O
was,O
used,O
to,O
analyze,O
categorical,O
data,O
.,O
 , 
Differences,O
were,O
considered,O
statistically,O
significant,O
at,O
a,O
level,O
of,O
P,O
<,O
0.05,O
.,O
 , 


,O
 , 
#1373649-01-Abstract-p01
*,O
*,O
IGNORE,O
LINE,O
*,O
*,O

,O
*,O
*,O
IGNORE,O
LINE,O
*,O
*,O

,O
*,O
*,O
IGNORE,O
LINE,O
*,O
*,O

,O
Microsatellite,O
instability,O
analysis,O
in,O
hereditary,B-disease
non,I-disease
-,I-disease
polyposis,I-disease
colon,B-body-part
cancer,I-disease
using,O
the,O
Bethesda,O
consensus,O
panel,O
of,O
microsatellite,O
markers,O
in,O
the,O
absence,O
of,O
proband,O
normal,O
tissue,O


,O
Abstract,O


,O
Background,O


,B-disease
Hereditary,I-disease
non,I-disease
-,I-disease
polyposis,I-disease
colon,B-body-part
cancer,I-disease
(,B-disease
HNPCC,I-disease
),I-disease
is,O
an,O
autosomal,B-Concepts_Ideas
dominant,I-Concepts_Ideas
syndrome,O
predisposing,O
to,O
the,O
early,B-Disorder
development,I-Disorder
of,O
various,O
cancers,B-disease
including,O
those,O
of,O
colon,B-body-part
,,I-body-part
rectum,B-body-part
,,I-body-part
endometrium,B-body-part
,,I-body-part
ovarium,B-body-part
,,I-body-part
small,B-body-part
bowel,I-body-part
,,I-body-part
stomach,B-body-part
and,O
urinary,B-body-part
tract,I-body-part
.,I-body-part
 , 
HNPCC,B-disease
is,O
caused,O
by,O
germline,B-mutation
mutations,I-mutation
in,I-mutation
the,I-mutation
DNA,I-mutation
mismatch,I-mutation
repair,I-mutation
genes,I-mutation
,,I-mutation
mostly,O
hMSH2,B-gene
or,O
hMLH1,B-gene
.,I-gene
 , 


,O
In,O
this,O
study,O
,,O
we,O
report,O
the,O
analysis,O
for,O
genetic,O
counseling,O
of,O
three,B-size
first,B-cohort-patient
-,I-cohort-patient
degree,I-cohort-patient
relatives,I-cohort-patient
(,O
the,O
mother,B-cohort-patient
and,O
two,B-size
sisters,B-gender
),I-gender
of,O
a,O
male,B-gender
who,O
died,O
of,O
colorectal,B-body-part
adenocarcinoma,B-disease
at,O
the,O
age,B-age
of,I-age
23,I-age
.,I-age
 , 
The,O
family,B-cohort-patient
fulfilled,O
strict,O
Amsterdam,O
-,O
I,O
criteria,O
(,O
AC,O
-,O
I,O
),O
with,O
the,O
presence,O
of,O
extracolonic,B-body-part
tumors,B-disease
in,O
the,O
extended,O
pedigree,O
.,O
 , 
We,O
overcame,O
the,O
difficulty,O
of,O
having,O
a,O
proband,B-cohort-patient
post,O
-,O
mortem,O
non,O
-,O
tumor,O
tissue,O
sample,O
for,O
MSI,O
testing,O
by,O
studying,O
the,O
alleles,O
carried,O
by,O
his,B-gender
progenitors,O
.,O
 , 


,O
Methods,O


,B-disease
Tumor,I-disease
MSI,O
testing,O
is,O
described,O
as,O
initial,O
screening,O
in,O
both,O
primary,O
and,O
metastasis,O
tumor,O
tissue,O
blocks,O
,,O
using,O
the,O
reference,O
panel,O
of,O
5,O
microsatellite,O
markers,O
standardized,O
by,O
the,O
National,O
Cancer,O
Institute,O
(,O
NCI,O
),O
for,O
the,O
screening,O
of,O
HNPCC,B-disease
(,O
BAT-25,O
,,O
BAT-26,O
,,O
D2S123,O
,,O
D5S346,O
and,O
D17S250,O
),O
.,O
 , 
Subsequent,O
mutation,O
analysis,O
of,O
the,O
hMLH1,B-gene
and,O
hMSH2,B-gene
genes,O
was,O
performed,O
.,O
 , 


,O
Results,O


,O
Three,O
of,O
five,O
microsatellite,O
markers,O
(,O
BAT-25,O
,,O
BAT-26,O
and,O
D5S346,O
),O
presented,O
different,O
alleles,O
in,O
the,O
proband,B-cohort-patient
's,I-cohort-patient
tumor,B-disease
as,O
compared,O
to,O
those,O
inherited,O
from,O
his,B-gender
parents,O
.,O
 , 
The,O
tumor,B-disease
was,O
classified,O
as,O
high,B-Disorder
frequency,I-Disorder
microsatellite,I-Disorder
instability,I-Disorder
(,B-Disorder
MSI,I-Disorder
-,I-Disorder
H,I-Disorder
),I-Disorder
.,O
 , 
We,O
identified,O
in,O
the,O
HNPCC,B-disease
family,B-cohort-patient
a,O
novel,O
germline,O
missense,B-mutation
(,B-mutation
c.1864C,I-mutation
>,I-mutation
A,I-mutation
),I-mutation
mutation,I-mutation
in,I-mutation
exon,I-mutation
12,I-mutation
of,O
hMSH2,B-gene
gene,O
,,O
leading,O
to,O
a,O
proline,B-mutation
622,I-mutation
to,I-mutation
threonine,I-mutation
(,B-mutation
p.,I-mutation
Pro622Thr,I-mutation
),I-mutation
amino,I-mutation
acid,I-mutation
substitution,I-mutation
.,I-mutation
 , 


,O
Conclusion,O


,O
This,O
approach,O
allowed,O
us,O
to,O
establish,O
the,O
tumor,B-disease
MSI,O
status,O
using,O
the,O
NCI,O
recommended,O
panel,O
in,O
the,O
absence,O
of,O
proband,O
's,O
non,O
-,O
tumor,O
tissue,O
and,O
before,O
sequencing,O
the,O
obligate,O
carrier,O
.,O
 , 
According,O
to,O
the,O
Human,O
Gene,O
Mutation,O
Database,O
(,O
HGMD,O
),O
and,O
the,O
International,O
Society,O
for,O
Gastrointestinal,O
Hereditary,O
Tumors,O
(,O
InSiGHT,O
),O
Database,O
this,O
is,O
the,O
first,O
report,O
of,O
this,O
mutation,O
.,O
 , 


,O
 , 
#1601966-03-Results-p06
*,O
*,O
IGNORE,O
LINE,O
*,O
*,O

,O
*,O
*,O
IGNORE,O
LINE,O
*,O
*,O

,O
*,O
*,O
IGNORE,O
LINE,O
*,O
*,O

,O
Up,O
-,O
regulation,O
of,O
mRNA,O
expression,O
in,O
human,O
chromosomal,O
region,O
12q21.1,O
-,O
q21.2,O
(,O
T,O
/,O
N,O
relative,O
expression,O
heat,O
map,O
),O
.,O
 , 
Heat,O
map,O
of,O
fold,O
change,O
of,O
tumor,B-disease
-,I-disease
versus,O
-,O
normal,O
expression,O
.,O
 , 
Genes,O
are,O
given,O
in,O
chromosomal,O
order,O
on,O
the,O
horizontal,O
axis,O
.,O
 , 
Patient,B-cohort-patient
codes,O
are,O
given,O
on,O
the,O
vertical,O
axis,O
.,O
 , 
The,O
legend,O
depicts,O
which,O
colors,O
code,O
for,O
which,O
expression,O
changes,O
on,O
a,O
loge,O
scale,O
(,O
green,O
:,O
down,O
in,O
tumor,B-disease
;,I-disease
red,O
:,O
up,O
in,O
tumor,B-disease
),I-disease
.,O
 , 
View,O
in,O
conjunction,O
with,O
Figures,O
16,O
and,O
17,O
.,O
 , 


,O
Up,O
-,O
regulation,O
of,O
mRNA,O
expression,O
in,O
human,O
chromosomal,O
region,O
12q21.1,O
-,O
q21.2,O
(,B-cohort-patient
patient,I-cohort-patient
counts,O
with,O
coordinate,O
up,O
-,O
regulation,O
),O
.,O
 , 
Grayscale,O
cross,O
-,O
comparison,O
plots,O
of,O
up,O
-,O
regulation,O
patterns,O
across,O
patients,B-cohort-patient
(,O
analogous,O
to,O
Figures,O
7,O
,,O
10,O
and,O
13,O
),O
.,O
 , 
View,O
this,O
plot,O
in,O
conjunction,O
with,O
Figures,O
15,O
and,O
17,O
.,O
 , 
Note,O
,,O
that,O
many,O
more,O
patients,B-cohort-patient
show,O
up,O
-,O
regulation,O
as,O
indicated,O
by,O
dark,O
spots,O
in,O
this,O
plot,O
than,O
down,O
-,O
regulation,O
as,O
indicated,O
by,O
dark,O
spots,O
in,O
Figure,O
17,O
.,O
 , 
Over,O
-,O
expressed,O
genes,O
in,O
this,O
region,O
comprise,O
leucine,O
-,O
rich,O
G,O
-,O
protein,O
coupled,O
receptor,O
5,O
(,O
GPR49,O
),O
,,O
HIV-1,O
rev,O
binding,O
protein,O
2,O
(,O
HRB2,O
),O
,,O
pleckstrin,O
-,O
homology,O
-,O
like,O
domain,O
family,B-cohort-patient
A,O
member,O
1,O
(,O
PHLDA1,O
),O
,,O
nucleosome,O
assembly,O
protein,O
1,O
-,O
like,O
1,O
(,O
NAP1L1,O
),O
,,O
oxysterol,O
binding,O
protein,O
-,O
like,O
8,O
(,O
OSBPL8,O
),O
,,O
cystein-,O
and,O
glycine,O
-,O
rich,O
protein,O
2,O
(,O
CSRP2,O
),O
,,O
E2F,O
transcription,O
factor,O
7,O
(,O
LOC144455,O
),O
.,O
 , 


,O
Up,O
-,O
regulation,O
of,O
mRNA,O
expression,O
in,O
human,O
chromosomal,O
region,O
12q21.1,O
-,O
q21.2,O
(,B-cohort-patient
patient,I-cohort-patient
counts,O
with,O
coordinate,O
down,O
-,O
regulation,O
),O
.,O
 , 
Grayscale,O
cross,O
-,O
comparison,O
plots,O
of,O
down,O
-,O
regulation,O
patterns,O
across,O
patients,B-cohort-patient
(,O
analogous,O
to,O
Figures,O
8,O
,,O
11,O
,,O
14,O
),O
.,O
 , 
View,O
this,O
plot,O
in,O
conjunction,O
with,O
Figures,O
15,O
and,O
16,O
.,O
 , 


,O
17q21.33,O
-,O
17q23.2,O


,O
The,O
chromosomal,O
interval,O
17q21.33,O
-,O
17q23.2,O
harbors,O
numerous,O
up,O
-,O
regulated,O
genes,O
(,O
see,O
Figures,O
18,O
,,O
19,O
,,O
20,O
),O
.,O
 , 
Chromosomal,O
gains,O
of,O
this,O
region,O
in,O
CRC,B-disease
have,O
been,O
described,O
by,O
two,O
independent,O
studies,O
[,O
21,25,O
],O
.,O
 , 
Up,O
to,O
18,B-size
of,I-size
25,I-size
patients,B-cohort-patient
show,O
up,O
-,O
regulation,O
of,O
expression,O
in,O
this,O
region,O
.,O
 , 
The,O
known,O
tumor,O
gene,O
NME1,B-gene
(,O
non,O
-,O
metastatic,O
1,O
;,O
encoding,O
the,O
NM23A,B-mutation
protein,O
,,O
a,O
nucleoside,O
diphosphate,O
kinase,O
),O
is,O
among,O
the,O
most,O
frequently,O
up,O
-,O
regulated,O
genes,O
in,O
this,O
region,O
.,O
 , 
Also,O
the,O
paralogous,O
genomic,O
neighbor,O
NME2,B-gene
which,O
acts,O
in,O
the,O
same,O
pathway,O
is,O
strongly,O
up,O
-,O
regulated,O
.,O
 , 
These,O
two,O
genes,O
are,O
possibly,O
the,O
primary,O
targets,O
of,O
regional,O
expression,O
up,O
-,O
regulation,O
.,O
 , 
However,O
,,O
up,O
-,O
regulation,O
of,O
several,O
other,O
genes,O
is,O
also,O
remarkable,O
.,O
 , 
The,O
up,O
-,O
regulation,O
of,O
the,O
mitochondrial,O
ribosomal,O
component,O
MRPS23,B-gene
is,O
notable,O
as,O
it,O
is,O
in,O
agreement,O
with,O
other,O
observations,O
of,O
up,O
-,O
regulation,O
of,O
genes,O
acting,O
in,O
translation,O
(,O
see,O
above,O
),O
.,O
 , 
Additionally,O
,,O
the,O
RING,O
finger,O
gene,O
FLJ20315,B-gene
/,B-gene
RNF124,I-gene
,,I-gene
possibly,O
encoding,O
a,O
novel,O
E3,O
ubiquitin,O
ligase,O
,,O
and,O
the,O
suppressor,O
of,O
Ty,O
4,O
homologue,O
1,O
(,B-gene
SUPT4H1,I-gene
),I-gene
,,O
a,O
putative,O
human,O
chromatin,O
regulator,O
that,O
alters,O
transcription,O
,,O
are,O
genes,O
that,O
are,O
strongly,O
up,O
-,O
regulated,O
and,O
could,O
have,O
the,O
potential,O
to,O
contribute,O
to,O
development,O
of,O
CRC,B-disease
.,I-disease
 , 


,O
Up,O
-,O
regulation,O
of,O
mRNA,O
levels,O
in,O
human,O
chromosomal,O
region,O
17q21.33,O
-,O
23.2,O
(,O
T,O
/,O
N,O
relative,O
expression,O
heat,O
map,O
),O
.,O
 , 
Heat,O
map,O
of,O
fold,O
change,O
of,O
tumor,B-disease
-,I-disease
versus,O
-,O
normal,O
expression,O
.,O
 , 
Genes,O
are,O
given,O
in,O
chromosomal,O
order,O
on,O
the,O
horizontal,O
axis,O
.,O
 , 
Patient,B-cohort-patient
codes,O
are,O
given,O
on,O
the,O
vertical,O
axis,O
.,O
 , 
The,O
legend,O
depicts,O
which,O
colors,O
code,O
for,O
which,O
expression,O
changes,O
on,O
a,O
loge,O
scale,O
(,O
green,O
:,O
down,O
in,O
tumor,B-disease
;,I-disease
red,O
:,O
up,O
in,O
tumor,B-disease
),I-disease
.,O
 , 
View,O
in,O
conjunction,O
with,O
Figures,O
19,O
and,O
20,O
.,O
 , 


,O
 , 
#1266026-02-Background-p01
*,O
*,O
IGNORE,O
LINE,O
*,O
*,O

,O
*,O
*,O
IGNORE,O
LINE,O
*,O
*,O

,O
*,O
*,O
IGNORE,O
LINE,O
*,O
*,O

,O
Background,O


,B-disease
Cancer,I-disease
is,O
thought,O
to,O
arise,O
through,O
a,O
multistep,O
process,O
involving,O
sequential,O
cycles,O
of,O
mutation,O
and,O
selection,O
[,O
1,O
],O
.,O
 , 
The,O
identities,O
and,O
numbers,O
of,O
mutations,O
required,O
for,O
transformation,O
are,O
uncertain,O
,,O
but,O
perhaps,O
six,O
general,O
cellular,O
functions,O
are,O
typically,O
altered,O
[,O
2,O
],O
.,O
 , 
Numbers,O
of,O
oncogenic,O
mutations,O
may,O
also,O
be,O
inferred,O
from,O
the,O
age,O
-,O
related,O
increases,O
in,O
frequencies,O
observed,O
with,O
many,O
cancer,B-disease
types,O
.,O
 , 
For,O
example,O
,,O
logarithms,O
of,O
cancer,B-disease
frequencies,O
versus,O
age,O
typically,O
yield,O
straight,O
lines,O
,,O
with,O
slopes,O
proportional,O
to,O
numbers,O
of,O
cancer,B-disease
mutations,O
[,O
3,O
],O
.,O
 , 


,B-body-part
Colorectal,I-body-part
cancer,I-disease
epidemiology,O
is,O
consistent,O
with,O
approximately,O
five,O
to,O
seven,O
oncogenic,O
mutations,O
before,O
transformation,O
[,O
3,O
-,O
6,O
],O
.,O
 , 
The,O
variability,O
in,O
estimated,O
numbers,O
of,O
mutations,O
may,O
reflect,O
a,O
number,O
of,O
differences,O
.,O
 , 
For,O
example,O
,,O
estimates,O
vary,O
between,O
populations,O
,,O
with,O
five,B-size
to,I-size
six,I-size
mutations,B-mutation
in,O
England,B-ethnicity
and,O
six,B-size
to,I-size
seven,I-size
mutations,B-mutation
in,O
Finland,B-ethnicity
[,O
4,O
],O
.,O
 , 
Recent,O
advances,O
in,O
cancer,B-disease
genetics,O
also,O
reveal,O
biologic,O
colorectal,B-disease
cancer,I-disease
heterogeneity,O
.,O
 , 
Approximately,O
5,B-size
%,I-size
of,O
all,O
colorectal,B-disease
cancers,B-cohort-patient
have,O
strong,O
familial,B-Concepts_Ideas
predispositions,O
and,O
arise,O
in,O
individuals,B-cohort-patient
with,O
germline,B-mutation
mutations,I-mutation
in,O
critical,O
susceptibility,O
loci,O
[,O
7,O
],O
.,O
 , 
Such,O
hereditary,B-Concepts_Ideas
cancers,B-disease
(,B-disease
familial,I-disease
adenomatous,I-disease
polyposis,I-disease
(,B-disease
FAP,I-disease
),I-disease
and,O
hereditary,B-disease
nonpolyposis,I-disease
colorectal,I-disease
cancer,I-disease
(,B-disease
HNPCC,I-disease
),I-disease
),O
typically,O
present,O
at,O
younger,B-age
ages,I-age
and,O
should,O
require,O
fewer,O
somatic,B-mutation
mutations,I-mutation
than,O
their,O
sporadic,O
counterparts,O
because,O
one,O
mutation,O
is,O
inherited,O
.,O
 , 


,O
Genetic,O
instability,O
also,O
divides,O
colorectal,B-disease
cancers,I-disease
into,O
two,B-size
groups,B-cohort-patient
[,O
8,O
],O
.,O
 , 
Approximately,O
10,B-size
to,I-size
15,I-size
%,I-size
of,O
sporadic,B-Concepts_Ideas
cancers,B-disease
exhibit,O
microsatellite,B-Disorder
instability,I-Disorder
(,O
MSI,O
),O
secondary,O
to,O
somatic,B-Physiology
loss,I-Physiology
of,I-Physiology
DNA,I-Physiology
mismatch,I-Physiology
repair,I-Physiology
(,B-gene
MMR,I-gene
),I-gene
.,O
 , 
Most,O
other,O
cancers,B-disease
exhibit,O
chromosomal,B-Disorder
instability,I-Disorder
(,B-Disorder
CIN,I-Disorder
),I-Disorder
characterized,O
by,O
aneuploidy,B-Disorder
and,O
loss,B-Physiology
of,I-Physiology
heterozygosity,I-Physiology
(,B-Physiology
LOH,I-Physiology
),I-Physiology
 , 
[,O
7,8,O
],O
.,O
 , 
CIN,B-Disorder
and,O
MSI+,B-Disorder
colorectal,B-disease
cancers,I-disease
have,O
different,O
characteristics,O
with,O
respect,O
to,O
mutated,O
loci,O
,,O
tumor,B-disease
location,O
,,O
morphology,O
,,O
and,O
clinical,O
outcomes,O
[,O
7,8,O
],O
.,O
 , 


,O
Numbers,O
of,O
oncogenic,O
mutations,O
may,O
differ,O
between,O
cancer,B-disease
subtypes,O
.,O
 , 
Therefore,O
,,O
colorectal,B-body-part
cancers,I-disease
arising,O
in,O
a,O
population,O
-,O
based,O
setting,O
were,O
molecularly,O
classified,O
as,O
either,O
sporadic,B-Concepts_Ideas
or,O
hereditary,B-Concepts_Ideas
,,I-Concepts_Ideas
and,O
MSI+,B-Disorder
or,O
MSI-,B-Disorder
.,I-Disorder
 , 
Cancers,B-disease
were,O
also,O
classified,O
with,O
respect,O
to,O
clinical,O
stage,O
because,O
additional,O
mutations,O
may,O
be,O
required,O
for,O
invasion,O
or,O
metastasis,O
.,O
 , 
Ages,O
at,O
cancer,B-disease
for,O
each,O
subgroup,O
were,O
used,O
to,O
infer,O
numbers,O
of,O
mutations,O
required,O
for,O
each,O
type,O
of,O
colorectal,B-body-part
cancer,B-disease
.,I-disease
 , 


,O
 , 
#3034663-01-Abstract-p01
Evidence,O
for,O
classification,O
of,O
c.1852_1853AA,B-mutation
>,I-mutation
GC,I-mutation
in,O
MLH1,B-gene
as,O
a,O
neutral,O
variant,O
for,O
Lynch,B-disease
syndrome,I-disease


,I-disease
Abstract,O


,O
Background,O


,B-disease
Lynch,I-disease
syndrome,I-disease
(,B-disease
LS,I-disease
),I-disease
is,O
an,O
autosomal,B-Concepts_Ideas
dominant,I-Concepts_Ideas
inherited,I-Concepts_Ideas
cancer,B-disease
syndrome,O
characterized,O
by,O
early,B-Disorder
onset,I-Disorder
cancers,B-disease
of,O
the,O
colorectum,B-body-part
,,I-body-part
endometrium,B-body-part
and,O
other,O
tumours,B-disease
.,I-disease
 , 
A,O
significant,O
proportion,O
of,O
DNA,O
variants,O
in,O
LS,B-disease
patients,B-cohort-patient
are,O
unclassified,O
.,O
 , 
Reports,O
on,O
the,O
pathogenicity,O
of,O
the,O
c.1852_1853AA,B-mutation
>,I-mutation
GC,I-mutation
(,B-mutation
p.,I-mutation
Lys618Ala,I-mutation
),I-mutation
variant,O
of,O
the,O
MLH1,B-gene
gene,O
are,O
conflicting,O
.,O
 , 
In,O
this,O
study,O
,,O
we,O
provide,O
new,O
evidence,O
indicating,O
that,O
this,O
variant,O
has,O
no,O
significant,O
implications,O
for,O
LS,B-disease
.,I-disease
 , 


,O
Methods,O


,O
The,O
following,O
approach,O
was,O
used,O
to,O
assess,O
the,O
clinical,O
significance,O
of,O
the,O
p.,B-mutation
Lys618Ala,I-mutation
variant,O
:,O
frequency,O
in,O
a,O
control,B-cohort-patient
population,I-cohort-patient
,,I-cohort-patient
case,O
-,O
control,O
comparison,O
,,O
co,O
-,O
occurrence,O
of,O
the,O
p.,B-mutation
Lys618Ala,I-mutation
variant,O
with,O
a,O
pathogenic,O
mutation,O
,,O
co,O
-,O
segregation,O
with,O
the,O
disease,O
and,O
microsatellite,B-Disorder
instability,I-Disorder
in,O
tumours,B-disease
from,O
carriers,B-cohort-patient
of,O
the,O
variant,O
.,O
 , 
We,O
genotyped,O
p.,B-mutation
Lys618Ala,I-mutation
in,O
1034,B-size
individuals,B-cohort-patient
(,B-size
373,I-size
sporadic,B-Concepts_Ideas
colorectal,B-disease
cancer,B-disease
[,B-disease
CRC,I-disease
],I-disease
patients,B-cohort-patient
,,I-cohort-patient
250,B-size
index,B-cohort-patient
subjects,I-cohort-patient
from,O
families,B-cohort-patient
suspected,O
of,O
having,O
LS,B-disease
[,O
revised,O
Bethesda,O
guidelines,O
],O
and,O
411,B-size
controls,B-cohort-patient
),I-cohort-patient
.,O
 , 
Three,B-size
well,O
-,O
characterized,O
LS,B-disease
families,B-cohort-patient
that,O
fulfilled,O
the,O
Amsterdam,O
II,O
Criteria,O
and,O
consisted,O
of,O
members,O
with,O
the,O
p.,B-mutation
Lys618Ala,I-mutation
variant,O
were,O
included,O
to,O
assess,O
co,O
-,O
occurrence,O
and,O
co,O
-,O
segregation,O
.,O
 , 
A,O
subset,O
of,O
colorectal,B-body-part
tumour,B-disease
DNA,O
samples,O
from,O
17,B-size
patients,B-cohort-patient
carrying,O
the,O
p.,B-mutation
Lys618Ala,I-mutation
variant,O
was,O
screened,O
for,O
microsatellite,O
instability,O
using,O
five,O
mononucleotide,O
markers,O
.,O
 , 


,O
Results,O


,B-size
Twenty,I-size
-,I-size
seven,I-size
individuals,B-cohort-patient
were,O
heterozygous,O
for,O
the,O
p.,B-mutation
Lys618Ala,I-mutation
variant,O
;,O
nine,B-cohort-patient
had,O
sporadic,B-Concepts_Ideas
CRC,B-disease
(,B-size
2.41,I-size
%,I-size
),I-size
,,O
seven,B-cohort-patient
were,O
suspected,O
of,O
having,O
hereditary,B-Concepts_Ideas
CRC,B-disease
(,B-size
2.8,I-size
%,I-size
),I-size
and,O
11,B-size
were,O
controls,B-cohort-patient
(,B-size
2.68,I-size
%,I-size
),I-size
.,O
 , 
There,O
were,O
no,O
significant,O
associations,O
in,O
the,O
case,O
-,O
control,O
and,O
case,O
-,O
case,O
studies,O
.,O
 , 
The,O
p.,B-mutation
Lys618Ala,I-mutation
variant,O
was,O
co,O
-,O
existent,O
with,O
pathogenic,B-mutation
mutations,I-mutation
in,O
two,B-size
unrelated,O
LS,B-disease
families,B-cohort-patient
.,I-cohort-patient
 , 
In,O
one,B-size
family,B-cohort-patient
,,I-cohort-patient
the,O
allele,O
distribution,O
of,O
the,O
pathogenic,O
and,O
unclassified,O
variant,O
was,O
in,O
trans,O
,,O
in,O
the,O
other,O
family,B-cohort-patient
the,O
pathogenic,O
variant,O
was,O
detected,O
in,O
the,O
MSH6,B-gene
gene,O
and,O
only,O
the,O
deleterious,O
variant,O
co,O
-,O
segregated,O
with,O
the,O
disease,O
in,O
both,O
families,B-cohort-patient
.,I-cohort-patient
 , 
Only,O
two,B-size
positive,B-cohort-patient
cases,I-cohort-patient
of,O
microsatellite,B-Disorder
instability,I-Disorder
(,B-size
2/17,I-size
,,I-size
11.8,B-size
%,I-size
),I-size
were,O
detected,O
in,O
tumours,B-disease
from,O
p.,B-mutation
Lys618Ala,I-mutation
carriers,O
,,O
indicating,O
that,O
this,O
variant,O
does,O
not,O
play,O
a,O
role,O
in,O
functional,B-Physiology
inactivation,I-Physiology
of,I-Physiology
MLH1,B-gene
in,O
CRC,B-disease
patients,B-cohort-patient
.,I-cohort-patient
 , 


,O
Conclusions,O


,O
The,O
p.,B-mutation
Lys618Ala,I-mutation
 , 
variant,O
should,O
be,O
considered,O
a,O
neutral,O
variant,O
for,O
LS,B-disease
.,I-disease
 , 
These,O
findings,O
have,O
implications,O
for,O
the,O
clinical,O
management,O
of,O
CRC,B-disease
probands,B-cohort-patient
and,O
their,O
relatives,B-cohort-patient
.,I-cohort-patient
 , 


,O
 , 
#2275286-03-Methods-p02
*,O
*,O
IGNORE,O
LINE,O
*,O
*,O

,O
*,O
*,O
IGNORE,O
LINE,O
*,O
*,O

,O
*,O
*,O
IGNORE,O
LINE,O
*,O
*,O

,O
The,O
DNA,O
sequence,O
of,O
each,O
microsatellite,O
in,O
the,O
tumor,B-disease
was,O
compared,O
with,O
that,O
of,O
the,O
matched,O
normal,B-disease
mucosa,B-body-part
.,I-body-part
 , 
It,O
was,O
considered,O
as,O
unstable,O
if,O
there,O
was,O
an,O
absence,O
,,O
shortening,O
or,O
prolongation,O
of,O
the,O
DNA,O
sequence,O
.,O
 , 
MSI,O
-,O
L,O
was,O
defined,O
as,O
1,O
unstable,O
microsatellite,O
out,O
of,O
5,O
,,O
while,O
MSI,O
-,O
H,O
was,O
defined,O
as,O
more,O
than,O
1,O
unstable,O
microsatellite,O
out,O
of,O
5,O
.,O
 , 
If,O
the,O
tumor,B-disease
microsatellites,O
were,O
identical,O
to,O
those,O
of,O
the,O
normal,O
tissue,O
,,O
the,O
microsatellite,O
was,O
considered,O
as,O
stable,O
(,O
MSS,O
),O
.,O
 , 


,O
For,O
the,O
MSI,B-Disorder
-,I-Disorder
L,I-Disorder
CRCs,B-disease
,,I-disease
BAT-40,O
and,O
MYCL,O
were,O
detected,O
.,O
 , 
If,O
either,O
of,O
these,O
two,O
markers,O
was,O
unstable,O
,,O
this,O
colorectal,B-body-part
sample,O
was,O
considered,O
as,O
MSI,O
-,O
H.,O


,O
Immunohistochemical,O
staining,O
for,O
MSH2,B-gene
,,I-gene
MSH6,B-gene
and,O
MLH1,B-gene
on,O
TMAs,O


,O
The,O
CRC,B-disease
microarray,O
was,O
constructed,O
as,O
previously,O
described,O
[,O
8,9,O
],O
.,O
 , 
Briefly,O
,,O
formalin,O
-,O
fixed,O
paraffin,O
-,O
embedded,O
tissue,O
blocks,O
of,O
CRC,B-disease
resections,O
were,O
cut,O
from,O
the,O
donor,O
block,O
and,O
stained,O
with,O
hematoxylin,O
-,O
eosin,O
(,O
HE,O
),O
.,O
 , 
These,O
slides,O
were,O
used,O
to,O
guide,O
the,O
sampling,O
from,O
morphologically,O
representative,O
regions,O
of,O
the,O
tissues,O
.,O
 , 
A,O
tissue,O
array,O
instrument,O
(,O
Beecher,O
Instruments,O
,,O
Silver,O
Spring,O
,,O
MD,O
),O
was,O
used,O
to,O
create,O
holes,O
in,O
a,O
recipient,O
paraffin,O
block,O
and,O
to,O
acquire,O
tissue,O
cores,O
from,O
the,O
donor,O
block,O
by,O
a,O
thin,O
-,O
walled,O
needle,O
with,O
an,O
inner,O
diameter,O
of,O
1.0,O
mm,O
,,O
held,O
in,O
an,O
X,O
-,O
Y,O
precision,O
guide,O
.,O
 , 
The,O
cylindrical,O
samples,O
were,O
retrieved,O
from,O
the,O
selected,O
regions,O
in,O
the,O
donors,O
and,O
extruded,O
directly,O
into,O
the,O
recipient,O
blocks,O
with,O
defined,O
array,O
coordinates,O
.,O
 , 
Three,O
cores,O
were,O
obtained,O
from,O
each,O
sample,O
.,O
 , 
After,O
the,O
construction,O
of,O
the,O
array,O
block,O
,,O
multiple,O
4,O
-,O
mm,O
thick,O
sections,O
were,O
cut,O
with,O
a,O
microtome,O
using,O
an,O
adhesive,O
-,O
coated,O
tape,O
sectioning,O
system,O
(,O
Instrumedics,O
,,O
Hackensack,O
,,O
NJ,O
),O
.,O
 , 
In,O
our,O
analysis,O
the,O
rates,O
of,O
lost,O
cases,B-cohort-patient
attributable,O
to,O
tissue,O
damage,O
were,O
less,O
than,O
5,O
%,O
for,O
the,O
different,O
markers,O
.,O
 , 


,O
TMA,O
slides,O
were,O
stained,O
with,O
MLH1,B-gene
antibodies,O
(,O
1:50,O
dilution,O
,,O
No,O
.,O
sc-494,O
,,O
Santa,O
Cruz,O
,,O
Biotrade,O
Ltd,O
,,O
Shanghai,O
,,O
China,O
),O
and,O
MSH2,B-gene
(,O
1:100,O
dilution,O
,,O
No,O
.,O
sc-581,O
,,O
Santa,O
Cruz,O
,,O
Biotrade,O
Ltd,O
,,O
Shanghai,O
,,O
China,O
),O
.,O
 , 
IHC,O
staining,O
for,O
samples,O
on,O
the,O
tissue,O
microarray,O
was,O
carried,O
out,O
using,O
Envision,O
ready,O
-,O
to,O
-,O
use,O
methods,O
(,O
Dako,O
Diagnostics,O
,,O
Zug,O
,,O
Switzerland,O
),O
.,O
 , 
Slides,O
were,O
deparaffinized,O
in,O
xylene,O
and,O
rehydrated,O
through,O
graded,O
concentrations,O
of,O
ethanol,O
to,O
distilled,O
water,O
,,O
and,O
endogenous,O
peroxidase,O
activity,O
was,O
blocked,O
by,O
incubation,O
with,O
30,O
mL,O
/,O
L,O
H2O2,O
in,O
methanol,O
for,O
10,O
min,O
at,O
room,O
temperature,O
.,O
 , 
Then,O
sections,O
were,O
submitted,O
to,O
antigen,O
retrieval,O
in,O
a,O
pressure,O
cooker,O
containing,O
0.01,O
mmol,O
/,O
L,O
natrium,O
citricium,O
buffer,O
for,O
10,O
min,O
.,O
 , 
Slides,O
were,O
subsequently,O
incubated,O
in,O
100,O
mL,O
/,O
L,O
normal,O
goat,O
serum,O
for,O
20,O
min,O
at,O
room,O
temperature,O
.,O
 , 
Sections,O
were,O
permeabilized,O
in,O
PBS,O
-,O
Triton,O
and,O
incubated,O
overnight,O
with,O
primary,O
antibody,O
at,O
4,O
°,O
C,O
.,O
 , 
The,O
pathologist,O
and,O
technician,O
who,O
reviewed,O
the,O
immunostaining,O
of,O
the,O
tissue,O
samples,O
were,O
blinded,O
to,O
the,O
patient,B-cohort-patient
's,I-cohort-patient
information,O
.,O
 , 
Stained,O
slides,O
and,O
individual,O
cores,O
were,O
scored,O
as,O
either,O
positive,O
(,O
showing,O
nuclear,O
staining,O
in,O
at,O
least,O
some,O
tumor,B-disease
cells,O
),O
or,O
negative,O
.,O
 , 


,O
 , 
#2275286-04-Results-p01
*,O
*,O
IGNORE,O
LINE,O
*,O
*,O

,O
*,O
*,O
IGNORE,O
LINE,O
*,O
*,O

,O
*,O
*,O
IGNORE,O
LINE,O
*,O
*,O

,O
Results,O


,B-size
One,I-size
hundred,I-size
fifty,I-size
-,I-size
eight,I-size
patients,B-cohort-patient
received,O
treatment,O
for,O
colorectal,B-disease
cancer,I-disease
in,O
our,O
Colorectal,B-body-part
Center,O
from,O
October,O
2004,O
to,O
June,O
2006,O
.,O
 , 
Three,B-size
patients,B-cohort-patient
were,O
excluded,O
for,O
concomitant,O
ulcerative,B-disease
colitis,I-disease
and,O
two,B-cohort-patient
for,O
unresectable,B-Physiology
diseases,B-disease
.,I-disease
 , 
Five,B-size
patients,B-cohort-patient
refused,O
operation,O
and,O
2,B-size
patients,B-cohort-patient
refused,O
to,O
participate,O
in,O
the,O
study,O
.,O
 , 
146,B-size
patients,B-cohort-patient
(,B-size
84,I-size
male,B-cohort-patient
and,O
62,B-size
female,B-cohort-patient
,,I-cohort-patient
age,O
:,O
60.8,B-age
±,I-age
10.5,I-age
yr,I-age
),I-age
were,O
recruited,O
into,O
the,O
study,O
.,O
 , 
Clinicopathological,O
features,O
of,O
those,O
patients,B-cohort-patient
are,O
summarized,O
in,O
Table,O
1,O
.,O
 , 


,O
Clinicopathological,O
features,O
of,O
cases,B-cohort-patient
(,O
N,O
=,O
146,B-size
),I-size


,O
*,O
Astler,O
-,O
Coller,O
Dukes,O
stage,O


,O
The,O
results,O
of,O
the,O
MSI,O
analysis,O
,,O
hypermethylation,O
of,O
MLH1,B-gene
and,O
IHC,O
staining,O
of,O
MSH2,B-gene
,,I-gene
MSH6,B-gene
and,O
MLH1,B-gene


,I-gene
With,O
the,O
original,O
NCI,O
five,O
marker,O
panel,O
,,O
34,B-size
of,I-size
146,I-size
patients,B-cohort-patient
(,B-size
23.2,I-size
%,I-size
),I-size
were,O
MSI,B-Disorder
,,I-Disorder
17,B-cohort-patient
were,O
MSI,B-Disorder
-,I-Disorder
H,I-Disorder
and,O
another,O
17,B-cohort-patient
were,O
MSI,B-Disorder
-,I-Disorder
L.,I-Disorder
Two,B-size
out,I-size
of,I-size
17,I-size
MSI,B-Disorder
-,I-Disorder
L,I-Disorder
CRCs,B-disease
were,O
unstable,B-Concepts_Ideas
with,I-Concepts_Ideas
BAT-40,I-Concepts_Ideas
and,O
were,O
judged,O
as,O
MSI,B-Disorder
-,I-Disorder
H.,I-Disorder
Seven,B-size
out,I-size
of,I-size
17,I-size
MSI,B-Disorder
-,I-Disorder
H,I-Disorder
CRCs,B-disease
were,O
unstable,B-Concepts_Ideas
with,I-Concepts_Ideas
BAT-40,I-Concepts_Ideas
.,I-Concepts_Ideas
 , 
In,O
all,O
,,O
19,B-size
CRCs,B-disease
(,B-size
55.9,I-size
%,I-size
),I-size
were,O
MSI,B-Disorder
-,I-Disorder
H,I-Disorder
and,O
15,B-size
cancers,B-disease
(,B-size
44.1,I-size
%,I-size
),I-size
were,O
MSI,B-Disorder
-,I-Disorder
L.,I-Disorder
 , 
The,O
remaining,O
112,B-size
patients,B-cohort-patient
(,B-size
76.8,I-size
%,I-size
were,O
MSS,B-Disorder
.,I-Disorder
 , 
In,O
the,O
MSI,B-Disorder
group,B-cohort-patient
,,I-cohort-patient
13,B-size
patients,B-cohort-patient
(,B-size
8.9,I-size
%,I-size
),I-size
were,O
BAT-26,B-Disorder
unstable,I-Disorder
,,I-Disorder
18,B-cohort-patient
(,B-size
12.3,I-size
%,I-size
),I-size
were,O
BAT-25,B-Disorder
unstable,I-Disorder
,,I-Disorder
16,B-size
(,B-size
11.0,I-size
%,I-size
),I-size
were,O
D2S123,B-Disorder
unstable,I-Disorder
,,I-Disorder
11,B-size
(,B-size
7.5,I-size
%,I-size
),I-size
were,O
D5S346,B-Disorder
unstable,I-Disorder
,,I-Disorder
14,B-size
(,B-size
9.6,I-size
%,I-size
),I-size
were,O
D17S250,B-Disorder
unstable,I-Disorder
.,I-Disorder
 , 


,B-Phenomena
Negative,I-Phenomena
staining,I-Phenomena
for,I-Phenomena
MSH2,B-gene
was,O
found,O
in,O
8,B-size
CRCs,B-disease
,,I-disease
negative,B-Phenomena
staining,I-Phenomena
for,I-Phenomena
MSH6,B-gene
was,O
found,O
in,O
6,B-size
CRCs,B-disease
.,I-disease
 , 
One,B-size
MSI,B-Disorder
-,I-Disorder
H,I-Disorder
CRC,B-disease
was,O
negative,B-Phenomena
for,I-Phenomena
both,I-Phenomena
MSH6,B-gene
and,I-Phenomena
MSH2,B-gene
.,I-gene
 , 
Seventeen,B-size
CRCs,B-disease
stained,B-Phenomena
negatively,I-Phenomena
for,I-Phenomena
MLH1,B-gene
.,I-gene
 , 
Negative,B-Phenomena
staining,I-Phenomena
was,I-Phenomena
not,I-Phenomena
found,I-Phenomena
in,O
three,B-size
MSI,B-Disorder
CRCs,B-disease
,,I-disease
and,O
one,B-size
CRC,B-disease
was,O
found,O
with,O
negative,B-Phenomena
MLH1,I-Phenomena
staining,I-Phenomena
,,I-Phenomena
but,O
it,O
was,O
MSS,B-Disorder
.,I-Disorder
 , 


,B-Physiology
MLH1,I-Physiology
promoter,I-Physiology
methylation,I-Physiology
was,O
determined,O
in,O
34,B-size
MSI,B-Disorder
CRCs,B-disease
.,I-disease
 , 
Hypermethylation,B-Physiology
of,I-Physiology
the,I-Physiology
MLH1,I-Physiology
promoter,I-Physiology
occurred,O
in,O
14,B-size
(,I-size
73.7,I-size
%,I-size
),I-size
out,I-size
of,I-size
19,I-size
MSI,B-Disorder
-,I-Disorder
H,I-Disorder
CRCs,B-disease
and,O
5,B-size
(,I-size
33.3,I-size
%,I-size
),I-size
out,I-size
15,I-size
MSI,B-Disorder
-,I-Disorder
L,I-Disorder
CRCs,B-disease
.,I-disease
 , 
The,O
results,O
of,O
MSI,O
and,O
IHC,O
staining,O
are,O
summarized,O
in,O
Table,O
2,O
.,O
 , 


,O
The,O
result,O
of,O
MSI,O
,,O
hypermethylation,O
of,O
MLH1,B-gene
and,O
IHC,O
staining,O


,O
*,B-size
One,I-size
MSI,B-Disorder
-,I-Disorder
H,I-Disorder
CRCs,B-disease
was,O
negative,B-Concepts_Ideas
both,I-Concepts_Ideas
for,I-Concepts_Ideas
MSH6,B-gene
and,I-Concepts_Ideas
MSH2,B-gene


,I-gene
#,O
MLH1,B-gene
promoter,I-Physiology
methylation,I-Physiology
was,O
determined,O
only,O
in,O
MSI,B-Disorder
CRCs,B-cohort-patient
.,I-cohort-patient
 , 


,O
Comparison,O
of,O
clinical,O
features,O
between,O
MSI,B-Disorder
and,O
MSS,B-Disorder
colorectal,B-disease
cancers,I-disease


,I-disease
Table,O
3,O
summarizes,O
the,O
clinical,O
features,O
of,O
MSS,B-Disorder
and,O
MSI,B-Disorder
patients,B-cohort-patient
.,I-cohort-patient
 , 
Patients,B-cohort-patient
in,O
the,O
MSS,B-Disorder
group,B-cohort-patient
are,O
younger,B-age
than,O
those,O
in,O
MSI,B-Disorder
group,B-cohort-patient
(,B-age
70.9,I-age
±,I-age
17.8,I-age
versus,O
61.0,B-age
±,I-age
9.4,I-age
,,I-age
p,O
=,O
0.045,O
),O
.,O
 , 
Twenty,B-size
out,I-size
of,I-size
34,I-size
(,B-size
59,I-size
%,I-size
),I-size
 , 
MSI,B-Disorder
patients,B-cohort-patient
were,O
stage,B-Concepts_Ideas
III,I-Concepts_Ideas
or,I-Concepts_Ideas
stage,I-Concepts_Ideas
IV,I-Concepts_Ideas
,,I-Concepts_Ideas
significantly,O
higher,O
than,O
those,O
(,B-size
35.7,I-size
%,I-size
),I-size
in,O
the,O
MSS,B-Disorder
group,B-cohort-patient
(,O
p,O
=,O
0.008,O
),O
.,O
 , 
There,O
were,O
no,O
differences,O
in,O
other,O
demographic,O
and,O
clinical,O
pathological,O
features,O
,,O
including,O
sex,O
,,O
tumor,B-disease
location,O
and,O
type,O
between,O
the,O
two,B-size
groups,B-cohort-patient
.,I-cohort-patient
 , 
The,O
most,O
common,O
location,O
of,O
the,O
tumor,B-disease
was,O
the,O
rectum,B-body-part
in,O
both,O
groups,B-cohort-patient
,,I-cohort-patient
accounting,O
for,O
more,B-size
than,I-size
50,I-size
%,I-size
of,O
the,O
cases,B-cohort-patient
.,I-cohort-patient
 , 
Adenocarcinoma,B-disease
was,O
the,O
most,O
common,O
pathological,O
type,O
in,O
both,O
groups,B-cohort-patient
.,I-cohort-patient
 , 
Ten,B-size
patients,B-cohort-patient
in,O
the,O
MSI,B-Disorder
group,B-cohort-patient
(,B-size
29.4,I-size
%,I-size
),I-size
had,O
mucinous,B-body-part
carcinoma,B-disease
.,I-disease
 , 


,O
 , 
#1360090-01-Abstract-p01
*,O
*,O
IGNORE,O
LINE,O
*,O
*,O

,O
*,O
*,O
IGNORE,O
LINE,O
*,O
*,O

,O
*,O
*,O
IGNORE,O
LINE,O
*,O
*,O

,O
mutations,O
are,O
associated,O
with,O
distinctive,O
clinical,O
,,O
pathological,O
and,O
molecular,O
features,O
of,O
colorectal,B-disease
cancer,I-disease
independently,O
of,O
microsatellite,O
instability,O
status,O


,O
Abstract,O


,O
Background,O


,B-gene
BRAF,I-gene
is,O
a,O
member,O
of,O
RAF,O
family,O
of,O
serine,O
/,O
threonine,O
kinases,O
and,O
mediates,O
cellular,O
responses,O
to,O
growth,O
signals,O
through,O
the,O
RAS,O
-,O
RAF,O
-,O
MAP,O
kinase,O
pathway,O
.,O
 , 
Activating,B-mutation
mutations,I-mutation
in,O
BRAF,B-gene
have,O
recently,O
been,O
found,O
in,O
about,O
10,B-size
%,I-size
of,O
colorectal,B-disease
cancers,B-cohort-patient
,,I-cohort-patient
with,O
the,O
vast,O
majority,O
being,O
a,O
V600E,B-mutation
hotspot,O
mutation,O
.,O
 , 
The,O
aim,O
of,O
the,O
present,O
study,O
was,O
to,O
evaluate,O
the,O
clinical,O
,,O
pathological,O
and,O
molecular,O
phenotype,O
of,O
colorectal,B-body-part
tumors,B-disease
with,O
BRAF,B-gene
mutations,B-mutation
.,I-mutation
 , 


,B-mutation
Results,O


,B-mutation
Mutations,I-mutation
in,I-mutation
BRAF,B-gene
were,O
identified,O
in,O
8,B-size
%,I-size
(,B-size
23/275,I-size
),I-size
of,O
colorectal,B-body-part
cancers,I-disease
.,I-disease
 , 
They,O
were,O
5–10,O
-,O
fold,O
more,O
frequent,O
in,O
tumors,B-disease
with,O
infiltrating,B-body-part
lymphocytes,I-body-part
,,I-body-part
location,O
in,O
the,O
proximal,B-body-part
colon,I-body-part
,,I-body-part
poor,B-Concepts_Ideas
histological,I-Concepts_Ideas
grade,I-Concepts_Ideas
and,O
mucinous,B-Concepts_Ideas
appearance,I-Concepts_Ideas
(,O
P,O
<,O
0.002,O
for,O
each,O
),O
.,O
 , 
Tumors,B-disease
with,O
BRAF,B-gene
mutation,B-mutation
were,O
also,O
10,O
-,O
fold,O
more,O
likely,O
to,O
show,O
microsatellite,B-Disorder
instability,I-Disorder
and,O
frequent,B-Physiology
DNA,I-Physiology
methylation,I-Physiology
(,O
P,O
<,O
0.0001,O
),O
compared,O
to,O
tumors,B-disease
without,O
this,O
mutation,O
.,O
 , 
The,O
characteristic,O
morphological,O
features,O
of,O
tumors,B-disease
with,O
BRAF,B-gene
mutation,B-mutation
(,B-body-part
infiltrating,I-body-part
lymphocytes,I-body-part
,,I-body-part
poor,B-Concepts_Ideas
grade,I-Concepts_Ideas
,,I-Concepts_Ideas
mucinous,B-Disorder
),I-Disorder
remained,O
after,O
stratification,O
according,O
to,O
microsatellite,O
instability,O
and,O
methylator,O
phenotypes,O
.,O
 , 
Mutations,B-mutation
in,O
BRAF,B-gene
were,O
mutually,O
exclusive,O
with,O
mutations,B-mutation
in,O
KRAS,B-gene
but,O
showed,O
no,O
clear,O
association,O
with,O
the,O
presence,O
of,O
TP53,B-gene
mutation,B-mutation
.,I-mutation
 , 


,O
Conclusion,O


,B-gene
BRAF,I-gene
mutation,B-mutation
identifies,O
a,O
colorectal,B-disease
cancer,B-disease
subgroup,O
with,O
distinctive,O
phenotypic,O
properties,O
independent,O
of,O
microsatellite,O
instability,O
status,O
and,O
thus,O
could,O
be,O
a,O
valuable,O
marker,O
for,O
studies,O
into,O
the,O
clinical,O
properties,O
of,O
these,O
tumors,B-disease
.,I-disease
 , 


,O
 , 
#3034663-02-Background-p02
The,O
MLH1,B-gene
p.,B-mutation
Lys618Ala,I-mutation
(,B-mutation
c.1852_1853AA,I-mutation
>,I-mutation
GC,I-mutation
),I-mutation
variant,O
was,O
initially,O
considered,O
a,O
deleterious,O
variant,O
based,O
on,O
its,O
recurrent,O
presence,O
in,O
LS,B-disease
families,B-cohort-patient
,,I-cohort-patient
in,O
silico,O
predictions,O
and,O
in,O
vitro,O
experiments,O
on,O
its,O
functional,O
effect,O
.,O
 , 
However,O
,,O
recent,O
data,O
on,O
its,O
co,O
-,O
segregation,O
with,O
LS,B-disease
have,O
cast,O
doubt,O
on,O
its,O
clinical,O
significance,O
[,O
6,O
],O
.,O
 , 
In,O
this,O
study,O
,,O
we,O
provide,O
evidence,O
supporting,O
the,O
contention,O
that,O
this,O
variant,O
has,O
no,O
significant,O
implications,O
in,O
LS,B-disease
.,I-disease
 , 


,O
The,O
following,O
approach,O
was,O
used,O
to,O
assess,O
the,O
clinical,O
significance,O
of,O
the,O
p.,B-mutation
Lys618Ala,I-mutation
variant,O
:,O
frequency,O
in,O
a,O
control,B-cohort-patient
population,I-cohort-patient
,,I-cohort-patient
case,O
-,O
control,O
and,O
case,O
-,O
case,O
comparisons,O
,,O
co,O
-,O
occurrence,O
with,O
a,O
pathogenic,O
mutation,O
,,O
co,O
-,O
segregation,O
with,O
the,O
disease,B-disease
and,O
MSI,B-Disorder
in,O
tumours,B-disease
from,O
carrier,B-cohort-patient
individuals,I-cohort-patient
.,I-cohort-patient
 , 


,O
 , 
#2386495-04-Results-p04
*,O
*,O
IGNORE,O
LINE,O
*,O
*,O

,O
*,O
*,O
IGNORE,O
LINE,O
*,O
*,O

,O
*,O
*,O
IGNORE,O
LINE,O
*,O
*,O

,O
Characterization,O
of,O
mutation,O
in,O
patient,B-cohort-patient
C633,B-cohort-patient
.,I-cohort-patient
 , 
Diagram,O
of,O
genomic,O
DNA,O
sequence,O
at,O
the,O
exon,O
/,O
intron,O
7,O
boundary,O
.,O
 , 
The,O
line,O
arrow,O
indicates,O
the,O
c.834,B-mutation
G,I-mutation
>,I-mutation
C,I-mutation
mutation,O
and,O
the,O
wildtype,O
5,O
',O
donor,O
splice,O
site,O
of,O
intron,O
7,O
is,O
underlined,O
in,O
the,O
sequence,O
diagram,O
.,O
 , 
The,O
wildtype,O
cDNA,O
and,O
the,O
resulting,O
amino,O
acid,O
sequence,O
from,O
the,O
corresponding,O
transcript,O
are,O
shown,O
above,O
the,O
diagram,O
.,O
 , 
The,O
G,O
that,O
is,O
substituted,O
in,O
one,O
allele,O
in,O
the,O
patient,B-cohort-patient
is,O
indicated,O
in,O
bold,O
.,O
 , 
The,O
cryptic,O
splice,O
site,O
used,O
as,O
a,O
result,O
of,O
the,O
mutation,O
is,O
underlined,O
with,O
a,O
dashed,O
line,O
and,O
the,O
shaded,O
area,O
corresponds,O
to,O
the,O
mRNA,O
sequence,O
deleted,O
in,O
the,O
mutant,O
transcript,O
.,O
 , 
Beneath,O
the,O
genomic,O
sequence,O
the,O
cDNA,O
sequence,O
derived,O
from,O
the,O
mutant,O
allele,O
is,O
displayed,O
,,O
showing,O
the,O
resulting,O
frameshift,O
and,O
premature,O
termination,O
of,O
the,O
translation,O
product,O
.,O
 , 


,O
A,O
family,B-cohort-patient
with,O
reduced,B-Physiology
APC,B-gene
expression,I-Physiology


,I-Physiology
Lowered,I-Physiology
APC,B-gene
expression,I-Physiology
was,O
observed,O
in,O
samples,O
from,O
two,B-size
affected,B-disease
individuals,B-cohort-patient
from,O
family,B-cohort-patient
1,I-cohort-patient
in,O
the,O
Swedish,B-ethnicity
Polyposis,B-disease
Registry,O
(,B-cohort-patient
index,I-cohort-patient
case,I-cohort-patient
,,I-cohort-patient
C152,B-cohort-patient
),I-cohort-patient
.,O
 , 
The,O
level,O
of,O
APC,B-gene
mRNA,O
expression,O
in,O
peripheral,B-body-part
blood,I-body-part
cells,I-body-part
from,O
these,O
two,B-size
individuals,B-cohort-patient
where,O
investigated,O
by,O
TaqMan,O
quantitative,O
RT,O
-,O
PCR,O
analysis,O
.,O
 , 
In,O
total,O
,,O
29,B-size
patients,B-cohort-patient
including,O
all,O
9,B-size
mutation,B-cohort-patient
-,I-cohort-patient
negative,I-cohort-patient
cases,I-cohort-patient
were,O
analyzed,O
.,O
 , 
APC-,B-gene
and,O
MUTYH,B-gene
-,B-mutation
mutation,I-mutation
positive,O
patients,B-cohort-patient
as,O
well,O
as,O
healthy,B-disease
individuals,B-cohort-patient
where,O
included,O
as,O
controls,O
.,O
 , 
Reduced,B-Physiology
APC,I-Physiology
expression,I-Physiology
was,O
only,O
observed,O
in,O
two,B-size
samples,B-cohort-patient
from,O
affected,B-disease
individuals,B-cohort-patient
and,O
both,O
of,O
those,O
where,O
from,O
family,B-cohort-patient
1,O
(,O
Figure,O
5A,O
),O
.,O
 , 
The,O
APC,B-gene
-,I-gene
mutation,I-mutation
positive,O
samples,O
used,O
as,O
controls,O
did,O
not,O
show,O
reduced,O
expression,O
of,O
APC,B-gene
.,I-gene
 , 
To,O
verify,O
the,O
expression,O
data,O
,,O
cDNA,O
from,O
the,O
individuals,B-cohort-patient
was,O
sequenced,O
over,O
an,O
informative,O
heterozygous,O
cSNP,O
position,O
(,B-mutation
c.5465A,I-mutation
>,I-mutation
T,I-mutation
),I-mutation
.,O
 , 
By,O
sequencing,O
cDNA,O
and,O
monitoring,O
the,O
level,O
of,O
expression,O
of,O
each,O
allele,O
as,O
shown,O
by,O
the,O
sequence,O
diagram,O
(,O
Figure,O
5B,O
),O
,,O
the,O
level,O
of,O
the,O
T,O
-,O
allele,O
was,O
found,O
to,O
be,O
lowered,O
in,O
the,O
two,B-size
FAP,B-disease
-,I-disease
affected,O
members,B-cohort-patient
of,I-cohort-patient
the,I-cohort-patient
family,I-cohort-patient
,,I-cohort-patient
compared,O
with,O
control,B-cohort-patient
individuals,I-cohort-patient
who,O
had,O
displayed,O
normal,B-Physiology
APC,B-gene
expression,I-Physiology
in,O
the,O
quantitative,O
RT,O
-,O
PCR,O
experiment,O
(,O
Figure,O
5A,O
),O
.,O
 , 
Linkage,O
to,O
the,O
APC,B-gene
locus,O
on,O
chromosome,O
5,O
has,O
also,O
been,O
investigated,O
in,O
this,O
family,B-cohort-patient
.,I-cohort-patient
 , 
Positive,O
linkage,O
in,O
two,O
different,O
branches,O
of,O
the,O
family,B-cohort-patient
was,O
determined,O
.,O
 , 
Individuals,B-cohort-patient
who,O
have,O
shown,O
positive,O
linkage,O
to,O
APC,B-gene
are,O
indicated,O
in,O
Figure,O
6,O
,,O
which,O
shows,O
a,O
pedigree,O
presenting,O
only,O
a,O
part,O
of,O
the,O
complete,O
pedigree,O
of,O
the,O
large,O
family,B-cohort-patient
1,I-cohort-patient
.,I-cohort-patient
 , 
In,O
total,O
,,O
this,O
family,B-cohort-patient
includes,O
150,B-size
individuals,B-cohort-patient
of,O
whom,O
57,B-cohort-patient
are,O
affected,B-cohort-patient
by,O
the,O
disease,B-disease
.,I-disease
 , 


,O
mRNA,O
expression,O
analysis,O
of,O
family,B-cohort-patient
1,I-cohort-patient
of,O
the,O
Swedish,B-ethnicity
Polyposis,B-disease
Registry,O
.,O
 , 
(,O
A,O
),O
Diagram,O
of,O
part,O
of,O
the,O
results,O
from,O
the,O
TaqMan,O
APC,B-gene
mRNA,O
expression,O
analysis,O
,,O
showing,O
the,O
relative,O
mRNA,O
levels,O
calculated,O
by,O
the,O
standard,O
curve,O
method,O
of,O
two,B-size
affected,B-disease
members,B-cohort-patient
of,I-cohort-patient
family,I-cohort-patient
1,I-cohort-patient
(,B-cohort-patient
A,I-cohort-patient
and,O
B,B-cohort-patient
),I-cohort-patient
and,O
two,B-size
control,B-cohort-patient
individuals,I-cohort-patient
(,B-cohort-patient
C,I-cohort-patient
and,O
D,B-cohort-patient
),I-cohort-patient
.,O
 , 
(,O
B,O
),O
Diagrams,O
of,O
cDNA,O
sequences,O
of,O
the,O
above,O
indicated,O
patients,B-cohort-patient
and,O
controls,B-cohort-patient
covering,O
the,O
APC,B-gene
c.5465A,B-mutation
>,I-mutation
T,I-mutation
polymorphism,O
.,O
 , 


,O
 , 
#3034663-06-Conclusions-p01
Conclusions,O


,O
Taken,O
together,O
,,O
the,O
results,O
of,O
this,O
study,O
and,O
others,O
indicate,O
that,O
the,O
c.1852_1853AA,B-mutation
>,I-mutation
GC,I-mutation
variant,O
should,O
be,O
considered,O
a,O
neutral,B-Concepts_Ideas
variant,I-Concepts_Ideas
for,O
LS,B-disease
.,I-disease
 , 
These,O
findings,O
have,O
considerable,O
relevance,O
for,O
the,O
clinical,O
management,O
of,O
CRC,B-disease
probands,B-cohort-patient
and,O
their,O
relatives,B-cohort-patient
.,I-cohort-patient
 , 


,O
 , 
#1601966-04-Discussion-p03
*,O
*,O
IGNORE,O
LINE,O
*,O
*,O

,O
*,O
*,O
IGNORE,O
LINE,O
*,O
*,O

,O
*,O
*,O
IGNORE,O
LINE,O
*,O
*,O

,O
Aberrantly,O
expressed,O
chromosomal,O
islands,O
linked,O
to,O
hereditary,O
cancer,O


,O
Roughly,O
5,B-size
%,I-size
of,O
all,O
colorectal,B-body-part
carcinomas,B-cohort-patient
are,O
hereditary,B-disease
non,I-disease
-,I-disease
polyposis,I-disease
colorectal,I-disease
cancers,I-disease
(,B-disease
HNPCCs,I-disease
),I-disease
.,O
 , 
In,O
HNPCC,B-disease
,,I-disease
histologically,O
verified,O
colorectal,B-body-part
carcinoma,B-disease
is,O
found,O
in,O
at,O
least,O
three,B-size
relatives,B-cohort-patient
from,O
two,O
or,O
more,O
successive,O
generations,O
.,O
 , 
In,O
at,O
least,O
one,O
patient,B-cohort-patient
,,I-cohort-patient
the,O
age,O
of,O
onset,O
should,O
be,O
less,B-age
than,I-age
50,I-age
years,I-age
.,I-age
 , 
Seven,O
chromosomal,O
regions,O
have,O
been,O
linked,O
to,O
HNPCC,B-disease
.,I-disease
 , 
More,O
than,O
half,O
of,O
these,O
HNPCC,B-disease
regions,O
show,O
misregulated,O
expression,O
in,O
our,O
patients,B-cohort-patient
.,I-cohort-patient
 , 
Three,O
regions,O
show,O
down,O
-,O
regulation,O
(,O
3p21.3,O
,,O
2q31,O
-,O
q33,O
comprising,O
PMS1,B-gene
,,I-gene
14q24.3,O
comprising,O
MLH3,B-gene
),I-gene
,,O
one,O
region,O
shows,O
up,O
-,O
regulation,O
(,O
7p22,O
comprising,O
PMS2,B-gene
),I-gene
,,O
and,O
three,O
regions,O
do,O
not,O
show,O
significant,O
changes,O
in,O
expression,O
(,O
2p22.p21,O
comprising,O
MSH2,B-gene
,,I-gene
2p16,O
comprising,O
MSH6,B-gene
,,I-gene
3p22,O
comprising,O
TGFBR2,B-gene
),I-gene
.,O
 , 
Eleven,O
further,O
chromosomal,O
regions,O
are,O
linked,O
to,O
hereditary,B-Concepts_Ideas
colorectal,B-body-part
carcinoma,B-disease
under,O
a,O
common,O
entry,O
in,O
OMIM,O
(,O
14500,O
),O
.,O
 , 
More,O
than,O
50,O
%,O
of,O
these,O
regions,O
show,O
significant,O
expression,O
changes,O
in,O
our,O
data,O
.,O
 , 
Five,O
regions,O
show,O
down,O
-,O
regulation,O
(,O
1p35,O
,,O
14q24.3,O
,,O
17p11.2,O
,,O
17p13.1,O
,,O
22q13,O
),O
,,O
one,O
region,O
shows,O
up,O
-,O
regulation,O
(,O
2p25,O
),O
,,O
and,O
five,O
regions,O
do,O
not,O
show,O
significant,O
expression,O
changes,O
in,O
our,O
data,O
(,O
3q26.3,O
,,O
8p22,O
-,O
p21.3,O
,,O
11p11.2,O
,,O
15q15,O
,,O
17q24,O
),O
.,O
 , 
In,O
combination,O
,,O
these,O
findings,O
strongly,O
suggest,O
that,O
expression,O
changes,O
in,O
regions,O
linked,O
to,O
hereditary,B-Concepts_Ideas
CRC,B-disease
play,O
a,O
role,O
in,O
CRC,B-disease
development,O
.,O
 , 


,O
Congruence,O
of,O
our,O
study,O
with,O
the,O
genome,O
-,O
wide,O
copy,O
number,O
and,O
expression,O
analysis,O
of,O
Tsafrir,O
et,O
al,O


,O
A,O
particular,O
focus,O
of,O
our,O
study,O
was,O
on,O
the,O
congruence,O
of,O
our,O
data,O
with,O
that,O
of,O
Tsafrir,O
et,O
al,O
.,O
 , 
[,O
17,O
],O
.,O
 , 
These,O
authors,O
described,O
11,O
alterations,O
of,O
whole,O
chromosomes,O
or,O
chromosome,O
arms,O
.,O
 , 
Using,O
our,O
approach,O
based,O
solely,O
on,O
expression,O
data,O
we,O
found,O
precisely,O
defined,O
region,O
of,O
coordinated,O
up,O
-,O
regulation,O
in,O
all,O
four,O
regions,O
of,O
gene,O
expression,O
and,O
gDNA,O
copy,O
number,O
gain,O
that,O
they,O
reported,O
(,O
+7,O
,,O
+8q,O
,,O
+13q,O
,,O
+20q,O
),O
.,O
 , 
For,O
six,O
of,O
seven,O
aberrations,O
(,O
-1p,O
,,O
-4,O
,,O
-5q,O
,,O
-14q,O
,,O
-15q,O
,,O
-18,O
),O
we,O
discovered,O
smaller,O
expression,O
islands,O
of,O
coordinated,O
down,O
-,O
regulation,O
.,O
 , 
We,O
were,O
not,O
able,O
to,O
reproduce,O
the,O
finding,O
of,O
expression,O
loss,O
on,O
8p,O
.,O
 , 
In,O
summary,O
,,O
this,O
large,O
congruence,O
of,O
our,O
results,O
with,O
that,O
of,O
Tsafrir,O
et,O
al,O
.,O
can,O
be,O
regarded,O
as,O
an,O
external,O
validation,O
of,O
our,O
results,O
.,O
 , 
The,O
comparison,O
illustrates,O
the,O
power,O
of,O
our,O
data,O
analysis,O
approach,O
which,O
allows,O
to,O
define,O
expression,O
islands,O
on,O
a,O
single,O
-,O
gene,O
resolution,O
.,O
 , 
Most,O
importantly,O
it,O
confirms,O
our,O
confidence,O
in,O
the,O
use,O
of,O
the,O
chip,O
platform,O
(,O
Affymetrix,O
U133A,O
),O
that,O
was,O
used,O
in,O
both,O
studies,O
and,O
apparently,O
can,O
lead,O
to,O
largely,O
congruent,O
results,O
in,O
different,O
patient,B-cohort-patient
cohorts,B-cohort-patient
and,O
laboratories,O
.,O
 , 


,O
 , 
#1557864-04-Results-p01
*,O
*,O
IGNORE,O
LINE,O
*,O
*,O

,O
*,O
*,O
IGNORE,O
LINE,O
*,O
*,O

,O
*,O
*,O
IGNORE,O
LINE,O
*,O
*,O

,O
Results,O


,O
Microsatellite,O
analysis,O


,O
Two,O
sublines,O
of,O
the,O
ovarian,B-body-part
cancer,I-disease
cell,B-cohort-patient
line,I-cohort-patient
A2780,B-cohort-patient
that,O
have,O
been,O
cultured,O
by,O
two,O
research,O
groups,O
in,O
our,O
department,O
and,O
the,O
cell,B-cohort-patient
lines,I-cohort-patient
SKOV3,B-cohort-patient
and,O
2774,B-cohort-patient
showed,O
a,O
microsatellite,B-Disorder
instable,I-Disorder
(,B-Disorder
MSI,I-Disorder
),I-Disorder
pattern,O
for,O
both,O
mononucleotide,O
markers,O
BAT25,O
and,O
BAT26,O
.,O
 , 
All,O
other,O
cell,B-cohort-patient
lines,I-cohort-patient
showed,O
no,B-Concepts_Ideas
aberrations,I-Concepts_Ideas
.,I-Concepts_Ideas
 , 
In,O
addition,O
,,O
the,O
75,B-size
ovarian,B-body-part
carcinoma,B-disease
tissues,B-cohort-patient
and,O
the,O
four,B-size
normal,B-disease
stromal,I-Disorder
controls,B-cohort-patient
showed,O
no,O
aberrations,O
for,O
BAT25,O
,,O
BAT26,O
and,O
BAT40,O
or,O
D2S123,O
,,O
indicating,O
that,O
these,O
are,O
microsatellite,B-Disorder
stable,I-Disorder
(,B-Disorder
MSS,I-Disorder
),I-Disorder
.,O
 , 


,B-gene
MLH1,I-gene
promoter,O
methylation,O


,B-size
One,I-size
of,I-size
the,I-size
two,I-size
A2780,B-cohort-patient
sublines,I-cohort-patient
showed,O
complete,O
methylation,B-Physiology
of,I-Physiology
the,I-Physiology
MLH1,B-gene
promoter,I-Physiology
while,O
the,O
other,O
showed,O
a,O
low,B-Physiology
level,I-Physiology
of,I-Physiology
methylation,I-Physiology
.,I-Physiology
 , 
The,O
results,O
for,O
HOC7,B-cohort-patient
and,O
2774,B-cohort-patient
were,O
not,O
informative,O
and,O
the,O
other,O
five,B-size
cell,B-cohort-patient
lines,I-cohort-patient
showed,O
no,B-Physiology
methylation,I-Physiology
.,I-Physiology
 , 
A,O
low,B-Physiology
level,I-Physiology
of,I-Physiology
MLH1,B-gene
promoter,I-Physiology
methylation,I-Physiology
was,O
also,O
seen,O
in,O
six,B-size
ovarian,B-body-part
carcinoma,B-disease
specimens,B-cohort-patient
and,O
in,O
addition,O
,,O
one,O
ovarian,B-body-part
carcinoma,B-disease
specimen,B-cohort-patient
showed,O
abundant,B-Physiology
methylation,I-Physiology
.,I-Physiology
 , 
Five,B-size
ovarian,B-body-part
carcinomas,B-cohort-patient
were,O
not,O
informative,O
while,O
the,O
other,O
63,B-size
ovarian,B-body-part
carcinomas,B-cohort-patient
showed,O
no,B-Physiology
methylation,I-Physiology
.,I-Physiology
 , 


,O
Quantitative,O
RT,O
-,O
PCR,O
:,O
expression,O
of,O
MLH1,B-gene
,,I-gene
MSH2,B-gene
,,I-gene
MSH3,B-gene
,,I-gene
MSH6,B-gene
and,O
PMS2,B-gene


,I-gene
The,O
mRNA,O
expression,O
data,O
for,O
the,O
cell,B-cohort-patient
lines,I-cohort-patient
is,O
shown,O
in,O
Figure,O
3A.,O
One,B-size
of,I-size
the,I-size
two,I-size
separately,O
cultured,O
MSI,B-Disorder
positive,I-Disorder
A2780,B-cohort-patient
cell,I-cohort-patient
lines,I-cohort-patient
showed,O
complete,B-Physiology
methylation,I-Physiology
of,I-Physiology
the,I-Physiology
MLH1,B-gene
promoter,I-Physiology
and,O
had,O
no,B-Physiology
mRNA,I-Physiology
expression,I-Physiology
of,I-Physiology
MLH1,B-gene
.,I-gene
 , 
The,O
other,O
A2780,B-cohort-patient
showed,O
a,O
low,B-Physiology
level,I-Physiology
of,I-Physiology
methylation,I-Physiology
but,O
had,O
the,O
highest,B-Physiology
MLH1,I-Physiology
expression,I-Physiology
levels,O
compared,O
to,O
the,O
other,O
cell,B-cohort-patient
lines,I-cohort-patient
.,I-cohort-patient
 , 
Of,O
the,O
other,O
two,B-size
MSI,B-Disorder
positive,I-Disorder
cell,B-cohort-patient
lines,I-cohort-patient
,,I-cohort-patient
SKOV3,B-cohort-patient
also,O
showed,O
no,B-Physiology
MLH1,B-gene
expression,I-Physiology
while,O
2774,B-cohort-patient
did,O
express,B-Physiology
MLH1,I-Physiology
mRNA,I-Physiology
.,I-Physiology
 , 


,O
RNA,O
was,O
available,O
for,O
50,B-size
of,I-size
the,I-size
75,I-size
ovarian,B-body-part
carcinomas,B-disease
and,O
the,O
mRNA,O
expression,O
data,O
for,O
these,O
carcinomas,B-disease
is,O
shown,O
in,O
Figure,O
3B.,O
Interestingly,O
,,O
the,O
ovarian,B-body-part
carcinoma,B-disease
with,O
an,O
abundant,B-Physiology
MLH1,B-gene
promoter,I-Physiology
methylation,I-Physiology
had,O
a,O
low,B-Physiology
MLH1,B-gene
mRNA,I-Physiology
expression,I-Physiology
compared,O
to,O
the,O
other,O
carcinomas,O
.,O
 , 
Thirty,B-size
-,I-size
six,I-size
of,I-size
the,I-size
50,I-size
patients,B-cohort-patient
received,O
platinum,O
-,O
based,O
chemotherapy,O
(,B-size
7,I-size
non,B-cohort-patient
-,I-cohort-patient
responders,I-cohort-patient
,,I-cohort-patient
28,B-size
responders,B-cohort-patient
and,O
one,O
patient,B-cohort-patient
with,O
unknown,O
response,O
),O
.,O
 , 
There,O
was,O
no,O
significant,O
association,O
between,O
the,O
response,O
to,O
platinum,O
-,O
based,O
chemotherapy,O
and,O
the,O
expression,O
of,O
each,O
of,O
these,O
genes,O
separately,O
(,O
Mann,O
-,O
Whitney,O
test,O
,,O
p,O
>,O
0.6,O
),O
.,O
 , 
Since,O
inactivation,O
of,O
only,O
one,O
of,O
these,O
genes,O
might,O
be,O
sufficient,O
to,O
cause,O
MMR,B-gene
deficiency,O
,,O
we,O
used,O
the,O
expression,O
of,O
all,O
of,O
the,O
five,O
genes,O
to,O
mark,O
MMR,B-gene
as,O
active,O
or,O
inactive,O
.,O
 , 
If,O
at,O
least,O
one,O
of,O
the,O
five,O
genes,O
had,O
an,O
expression,O
in,O
the,O
lowest,O
quartile,O
we,O
marked,O
MMR,B-gene
as,O
inactive,O
.,O
 , 
If,O
none,O
of,O
the,O
genes,O
had,O
an,O
expression,O
in,O
the,O
lowest,O
quartile,O
MMR,B-gene
was,O
marked,O
as,O
active,O
(,O
Figure,O
3B,O
),O
.,O
 , 
Next,O
the,O
Mann,O
-,O
Whitney,O
test,O
demonstrated,O
that,O
there,O
was,O
no,O
significant,O
relation,O
between,O
the,O
deducted,O
MMR,B-gene
status,O
and,O
response,O
to,O
platinum,O
-,O
based,O
chemotherapy,O
(,O
p,O
=,O
0.665,O
),O
.,O
 , 


,O
 , 
#1601966-03-Results-p09
*,O
*,O
IGNORE,O
LINE,O
*,O
*,O

,O
*,O
*,O
IGNORE,O
LINE,O
*,O
*,O

,O
*,O
*,O
IGNORE,O
LINE,O
*,O
*,O

,O
Down,O
-,O
regulation,O
of,O
mRNA,O
expression,O
in,O
human,O
chromosomal,O
region,O
4p15.31,O
-,O
15.2,O
(,O
T,O
/,O
N,O
relative,O
expression,O
heat,O
map,O
),O
.,O
 , 
Heat,O
map,O
of,O
fold,O
change,O
of,O
tumor,B-disease
-,I-disease
versus,O
-,O
normal,O
expression,O
.,O
 , 
Genes,O
are,O
given,O
in,O
chromosomal,O
order,O
on,O
the,O
horizontal,O
axis,O
.,O
 , 
Patient,B-cohort-patient
codes,O
are,O
given,O
on,O
the,O
vertical,O
axis,O
.,O
 , 
The,O
legend,O
depicts,O
which,O
colors,O
code,O
for,O
which,O
expression,O
changes,O
on,O
a,O
loge,O
scale,O
(,O
green,O
:,O
down,O
in,O
tumor,B-disease
;,I-disease
red,O
:,O
up,O
in,O
tumor,B-disease
),I-disease
.,O
 , 
View,O
in,O
conjunction,O
with,O
Figures,O
22,O
and,O
23,O
.,O
 , 


,O
Down,O
-,O
regulation,O
of,O
mRNA,O
expression,O
in,O
human,O
chromosomal,O
region,O
4p15.31,O
-,O
15.2,O
(,B-cohort-patient
patient,I-cohort-patient
counts,O
with,O
coordinate,O
up,O
-,O
regulation,O
),O
.,O
 , 
Grayscale,O
cross,O
-,O
comparison,O
plot,O
of,O
up,O
-,O
regulation,O
patterns,O
across,O
patients,B-cohort-patient
(,O
analogous,O
to,O
Figures,O
7,O
,,O
10,O
,,O
13,O
),O
.,O
 , 
View,O
this,O
plot,O
in,O
conjunction,O
with,O
Figures,O
21,O
and,O
23,O
.,O
 , 


,O
Down,O
-,O
regulation,O
of,O
mRNA,O
expression,O
in,O
human,O
chromosomal,O
region,O
4p15.31,O
-,O
15.2,O
(,B-cohort-patient
patient,I-cohort-patient
counts,O
with,O
coordinate,O
down,O
-,O
regulation,O
),O
.,O
 , 
Grayscale,O
cross,O
-,O
comparison,O
plot,O
of,O
down,O
-,O
regulation,O
patterns,O
across,O
patients,B-cohort-patient
(,O
analogous,O
to,O
Figures,O
8,O
,,O
11,O
,,O
14,O
),O
.,O
 , 
View,O
this,O
plot,O
in,O
conjunction,O
with,O
Figures,O
21,O
and,O
22,O
.,O
 , 
Note,O
,,O
that,O
many,O
more,O
patients,B-cohort-patient
show,O
down,O
-,O
regulation,O
as,O
indicated,O
by,O
dark,O
spots,O
in,O
this,O
plot,O
than,O
up,O
-,O
regulation,O
as,O
indicated,O
by,O
dark,O
spots,O
in,O
Figure,O
22,O
.,O
 , 
This,O
region,O
has,O
been,O
reported,O
in,O
other,O
studies,O
to,O
be,O
frequently,O
deleted,O
in,O
colon,B-body-part
cancer,I-disease
(,O
see,O
Table,O
4,O
),O
.,O
 , 
Note,O
the,O
expression,O
down,O
-,O
regulation,O
of,O
SLIT2,B-gene
,,I-gene
GPR125,B-gene
and,O
PCDH7,B-gene
.,I-gene
 , 


,O
18q21.2,O
-,O
18q23,O


,O
There,O
are,O
several,O
reports,O
of,O
loss,O
of,O
chromosome,O
18q,O
in,O
CRC,B-disease
(,O
see,O
Tables,O
1,O
and,O
4,O
),O
.,O
 , 
We,O
found,O
a,O
smaller,O
region,O
of,O
expression,O
down,O
-,O
regulation,O
at,O
18q21.2,O
-,O
18q23,O
(,O
see,O
Figures,O
24,O
,,O
25,O
,,O
26,O
),O
.,O
 , 
There,O
is,O
a,O
hot,O
spot,O
for,O
down,O
-,O
regulation,O
in,O
direct,O
vicinity,O
of,O
the,O
BCL2,B-gene
gene,O
.,O
 , 
Its,O
special,O
role,O
in,O
cancer,O
qualified,O
the,O
anti,O
-,O
apoptotic,O
BCL2,B-gene
protein,O
as,O
a,O
therapeutic,O
target,O
molecule,O
[,O
34,35,O
],O
.,O
 , 
Here,O
we,O
observed,O
down,O
-,O
regulation,O
of,O
BCL2,B-gene
and,O
its,O
neighbors,O
which,O
is,O
contradictory,O
to,O
its,O
known,O
anti,O
-,O
apoptotic,O
cancer,B-disease
-,I-disease
promoting,O
function,O
.,O
 , 
Distal,O
to,O
BCL2,B-gene
at,O
18q21.1,O
-,O
18q21.2,O
there,O
is,O
a,O
region,O
of,O
less,O
pronounced,O
down,O
-,O
regulation,O
between,O
ME2,B-gene
and,O
MBD2,B-gene
.,I-gene
 , 
The,O
SMAD4,B-gene
(,O
Hs.298320,O
),O
is,O
only,O
weakly,O
down,O
-,O
regulated,O
and,O
the,O
biological,O
significance,O
is,O
questionable,O
.,O
 , 
The,O
DCC,B-gene
(,B-mutation
deleted,I-mutation
in,O
colorectal,B-body-part
carcinoma,B-disease
),I-disease
,,O
proximal,O
to,O
MBD2,B-gene
,,I-gene
is,O
the,O
largest,O
gene,O
in,O
this,O
region,O
,,O
but,O
no,O
statements,O
about,O
its,O
expression,O
can,O
be,O
made,O
because,O
of,O
a,O
lack,O
of,O
informative,O
expression,O
measures,O
.,O
 , 
The,O
SMAD2,B-gene
and,O
SMAD7,B-gene
genes,O
are,O
in,O
close,O
vicinity,O
to,O
this,O
region,O
.,O
 , 
In,O
summary,O
,,O
we,O
do,O
not,O
have,O
direct,O
evidence,O
for,O
down,O
-,O
regulation,O
of,O
tumor,B-disease
suppressor,O
genes,O
in,O
this,O
region,O
.,O
 , 
Instead,O
,,O
we,O
observed,O
down,O
-,O
regulation,O
of,O
the,O
cancer,B-disease
-,I-disease
promoting,O
BCL2,B-gene
gene,O
.,O
 , 
Therefore,O
,,O
the,O
biological,O
significance,O
of,O
this,O
domain,O
of,O
expression,O
loss,O
remains,O
elusive,O
.,O
 , 
Possibly,O
,,O
the,O
down,O
-,O
regulation,O
of,O
the,O
BCL2,B-gene
region,O
is,O
just,O
a,O
by,O
-,O
stander,O
effect,O
of,O
deletions,O
targeted,O
at,O
DCC,B-gene
disruption,O
.,O
 , 
Alternatively,O
,,O
BCL2,B-gene
down,O
-,O
regulation,O
could,O
be,O
an,O
unsuccessful,O
attempt,O
of,O
the,O
tumor,B-disease
cells,O
',O
genetic,O
program,O
to,O
shift,O
the,O
cellular,O
homeostasis,O
towards,O
cell,O
death,O
.,O
 , 


,O
 , 
